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ABSTRACT 
The overall aim of the thesis was to describe the broad variability in neurodevelopmental 
profiles in preschool children with autism spectrum disorders (ASD) and to relate these findings 
to co-existing genetic conditions and other medical disorders. Children in the study were 
assessed with regard to neurodevelopmental characteristics, before and after intervention, and 
were recommended genetic testing including chromosomal micro-array.  Data concerning 
parental and sibling neuropsychiatric conditions were also collected.  
PAPER 1 
The objective of the first study was to characterize ASD severity, general cognitive and 
language level and associated co-existing disorders in a population-based group of 208 
preschool children (age 20-54 months at first assessment) with a clinical diagnosis of ASD, 
before the initiation of early intervention at the Autism Centre for Young Children, in 
Stockholm County. The study set up base-line data for a 2-year follow-up regarding outcome 
based on adaptive functions. Intellectual disability and developmental delay were found in a 
large proportion as well as hyperactivity. A regressive trajectory was found in one fifth and 
epilepsy in 6 %. 
PAPER II 
In the second study, certain prenatal risk factors were studied in the group of 208 preschool 
children with early-diagnosed ASD and the data were contrasted to the general population, 
using the Swedish Medical Birth register. Compared to the general population, fathers of 
children with ASD were older and parents more often of non-European origin. Mothers of 
children with ASD had an increased rate of antidepressant and psychoactive medication use, 
as well as of scheduled caesarean sections. At parental interview, information was also 
obtained regarding developmental and psychiatric disorders in the family. Fathers and 
brothers of children with ASD had high rates of ASD including the broader phenotype. 
Mothers of children with ASD had high rates of depression and other psychiatric disorders. 
PAPER III 
The third study reports all available medical information regarding the 208 children with ASD 
and preliminary results from genetic analyses. All children had received early intervention, 
intensive or non-intensive. Outcome at the two-year follow up was measured as change in 
adaptive function, according to Vineland composite score. A significant genetic or other 
medical condition was found in 18%. Epilepsy prevalence was now 8.6%. Children with a 
medical/genetic condition, including epilepsy, had been diagnosed with ASD at an earlier age 
than those without such conditions and the presence of an identified medical disorder 
correlated negatively with adaptive functioning outcome. 
PAPER IV 
In the fourth study, 162 of the 208 children with early-diagnosed ASD were analysed with 
chromosomal micro-array analysis to detect Copy Number Variants (CNVs) associated as risk 
factors for autism. Pathogenic aberrations were detected in 8.6 % of the patients, and in an 
additional 8.6 % variants of uncertain significance were present. CNVs were more frequent in 
children with congenital malformations or dysmorphic features as well as in children with 
intellectual disability in addition to ASD. Finally, we explored how parentally transmitted 
CNVs related to neurodevelopmental and psychiatric conditions in the parents. There was a 
trend towards increased rates of neurodevelopmental and psychiatric conditions in mothers 
transmitting a potentially pathogenic CNV compared to the mothers of children where no CNV 
was detected. 
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1 INTRODUCTION AND BACKGROUND 
 
Autism Spectrum Disorders (ASDs) represent a clinically and aetiologically highly 
heterogeneous group of neurodevelopmental conditions characterized by qualitative 
impairments in reciprocal social interaction and communication and by restricted, 
repetitive, stereotyped interests and behaviours. There is a considerable variation in 
clinical symptoms in individuals within the autism spectrum. In many individuals with 
ASD there are co-existing disorders, such as intellectual disability (ID), ADHD and 
other psychiatric conditions. The severity of social and communicative impairment 
varies greatly as well as the cognitive level. Intellectual disability is reported in 
approximately 70% of children with autistic disorder [1-3]. Within the total autism 
spectrum, ID is reported in ~50 % in preschool children [3] and in ~15% in school 
children [4]. Language and communication impairments in ASD include a spectrum 
varying from severe impairments with extremely low verbal skills to impairments in 
pragmatic language skills as well as those with more than average language capacity.   
 
Definitions and classification of autism spectrum disorders 
 
In 1943 Leo Kanner published a paper describing 11 cases, “Autistic disturbances of 
affective contact” [5]. In 1944, Hans Asperger described four male cases with similar 
but less severe impairments and with higher cognitive function [6]. In the earliest 
Diagnostic and Statistical Manuals of Mental Disorders (DSM-I 1952 and DSM-II 
1968) autism was considered to belong to the childhood onset schizophrenia group.  
Between the 1950s and the 1970s, autism was assumed to be caused by psychogenic 
factors and due to poor parenting. The criteria for childhood autism proposed by 
Michael Rutter in 1978 influenced the DSM III (1980) and infantile autism was no 
longer included among the childhood schizophrenia disorders.  
 
In the DSM-IV, autism conditions included Autistic disorder (AD), Pervasive 
developmental Disorder Not Otherwise Specified, (PDD-NOS), Asperger Syndrome 
and Childhood Disintegrative Disorder [7]. The WHO ASD classification (International 
Classification of Diseases, ICD-10, 1992), is commonly used in the Swedish Hospital 
and Medical diagnostic registers [8].  In ICD-10, the term PDD-NOS is replaced by 
atypical autism. 
 
Autistic disorder is usually considered to be the most severe form with onset before 3 
years of age. Pervasive developmental Disorder Not Otherwise Specified or Atypical 
Autism requires fewer criteria and can be regarded as a less severe form of ASD than 
AD. In Asperger syndrome the criteria includes significant impairment in social 
interaction and restrictive and repetitive interest and behaviour.  
 
In the newly launched DSM-5, there is one single umbrella term - Autism Spectrum 
Disorder, officially recognizing what has been the de-facto term in recent years. 
Asperger syndrome and PDD-NOS are excluded, and are no longer diagnostic entities. 
The rationale for these major changes from categorical to dimensional criteria was 
influenced by a US multisite study that demonstrated that “clinical distinctions among 
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categorical diagnostic subtypes of autism spectrum disorders were not reliable even 
across sites with well-documented fidelity using standardized diagnostic instruments” 
[9]. 
 
Current DSM-5 criteria now include impairments in two major domains - Persistent 
deficits in social communication and social interaction and restricted, repetitive patterns 
of behaviour, interests or activities.  The diagnostic practice requires specification of 
additional information including severity level of ASD, level of adaptive functioning 
and other important features (such as presence or not of known genetic disorder, 
epilepsy, and intellectual disability). Symptoms must be present in early childhood (but 
may not become fully manifest until social demands exceed limited capacities) and 
limit and impair everyday functioning [10].  
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Diagnostic Criteria for Autistic Disorder DSM IV 
 
A. A total of six or more items from (1), (2), and (3), with at least two from (1), and one each from (2) and (3): 
(1) Qualitative impairment in social interaction, as manifested by at least two of the following: 
(a) marked impairment in the use of multiple nonverbal behaviours such as eye-to-eye gaze, facial expression, body 
postures, and gestures to regulate social interaction 
(b) failure to develop peer relationships appropriate to developmental level 
(c) lack of spontaneous seeking to share enjoyment, interests, or achievements with other people (e.g., by a lack of 
showing, bringing, or pointing out objects of interest) 
(d) lack of social or emotional reciprocity 
(2) Qualitative impairments in communication as manifested by at least one of the following: 
(a) delay in, or total lack of, the development of spoken language (not accompanied by an attempt to compensate 
through alternative modes of communication such as gesture or mime) 
(b) in individuals with adequate speech, marked impairment in the ability to initiate or sustain a conversation with 
others  
(c) stereotyped and repetitive use of language or idiosyncratic language 
(d) lack of varied, spontaneous make-believe play or social imitative play appropriate to developmental level 
(3) Restricted repetitive and stereotyped patterns of behaviour, interests, and activities, as manifested by at least one 
of the following: 
(a) encompassing preoccupation with one or more stereotyped and restricted patterns of interest that is abnormal 
either in intensity or focus 
(b) apparently inflexible adherence to specific, non-functional routines or rituals 
(c) stereotyped and repetitive motor manners (e.g., hand or finger flapping or twisting, or complex whole-body 
movements) 
(d) persistent preoccupation with parts of objects 
B. Delays or abnormal functioning in at least one of the following areas, with   onset prior to age 3 years: (1) social 
interaction, (2) language as used in social communication, or (3) symbolic or imaginative play. 
C. The disturbance is not better accounted for by Rett’s Disorder or Childhood Disintegrative Disorder. 
 
 
 
 
 
Diagnostic Criteria Pervasive Developmental Disorder Not Otherwise Specified (Including Atypical Autism) 
DSM IV 
 
Severe and pervasive impairment in the development of reciprocal social interaction associated with impairment in 
either verbal or nonverbal communication skills or with the presence of stereotyped behaviour, interests, and 
activities, but the criteria are not met for a specific Pervasive Developmental Disorder, Schizophrenia, Schizotypal 
Personality Disorder or Avoidant Personality Disorder.  
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 Diagnostic Criteria for Asperger's Disorder DSM IV 
 
A. Qualitative impairment in social interaction, as manifested by at least two of the following: 
a) marked impairment in the use of multiple nonverbal behaviours such as eye-to eye gaze,  facial expression, 
body postures, and gestures to regulate social interaction 
b) failure to develop peer relationships appropriate to developmental level 
c) lack of spontaneous seeking to share enjoyment, interests, or achievements with other people (e.g., by a lack 
of showing, bringing, or pointing out objects of interest to other people) 
d) lack of social or emotional reciprocity 
B. Restricted repetitive and stereotyped patterns of behaviour, interests and activities, as manifested       
a) encompassing preoccupation with one or more stereotyped and restricted patterns of interest that is abnormal 
either in intensity of focus 
b) apparently inflexible adherence to specific, non-functional routines or rituals 
c) stereotyped and repetitive motor mannerisms (e.g., hand or finger flapping or twisting, or complex whole-
body movements) 
d) persistent preoccupation with parts of objects 
C. The disturbance causes clinically significant impairment in social, occupational, or other important areas of 
functioning.  
D. There is no clinically significant general delay in language (e.g., single words used by age 2 years, 
communicative phrases used by age 3 years). 
E. There is no clinically significant delay in cognitive development or in the development of age-appropriate 
self-help skills, adaptive behaviour (other than in social interaction), and curiosity about the environment in 
childhood. 
F. Criteria are not met for another specific Pervasive Developmental Disorder or Schizophrenia. 
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DSM-5 Criteria for Autism Spectrum Disorder 
An individual must meet criteria A, B, C and D: 
A. Persistent deficits in social communication and social interaction across contexts, not accounted for by general 
developmental delays, and manifest by all 3 of the following: 
1. Deficits in social-emotional reciprocity; ranging from abnormal social approach and failure of normal back and 
forth conversation through reduced sharing of interests, emotions, and affect and response to total lack of initiation of 
social interaction. 
2. Deficits in nonverbal communicative behaviours used for social interaction; ranging from poorly integrated- verbal 
and nonverbal communication, through abnormalities in eye contact and body-language, or deficits in understanding 
and use of nonverbal communication, to total lack of facial expression or gestures. 
3. Deficits in developing and maintaining relationships, appropriate to developmental level (beyond those with 
caregivers); ranging from difficulties adjusting behaviour to suit different social contexts through difficulties in 
sharing imaginative play and in making friends to an apparent absence of interest in people. 
B. Restricted, repetitive patterns of behaviour, interests, or activities as manifested by at least two of the following: 
1. Stereotyped or repetitive speech, motor movements, or use of objects; (such as simple motor stereotypies, 
echolalia, repetitive use of objects, or idiosyncratic phrases). 
2. Excessive adherence to routines, ritualized patterns of verbal or nonverbal behaviour, or excessive resistance to 
change; (such as motoric rituals, insistence on same route or food, repetitive questioning or extreme distress at small 
changes). 
3. Highly restricted, fixated interests that are abnormal in intensity or focus; (such as strong attachment to or 
preoccupation with unusual objects, excessively circumscribed or perseverative interests). 
4. Hyper-or hypo-reactivity to sensory input or unusual interest in sensory aspects of environment; (such as apparent 
indifference to pain/heat/cold, adverse response to specific sounds or textures, excessive smelling or touching of 
objects, fascination with lights or spinning objects). 
C. Symptoms must be present in early childhood (but may not become fully    manifest until social demands exceed 
limited capacities) 
D. Symptoms together limit and impair everyday functioning 
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Prevalence of ASD 
 
The broad spectrum of ASDs is relatively common, affecting approximately 0.6-1% of 
the childhood population [1, 11, 12]. However, the prevalence of the most severe 
Autistic Disorder is often estimated 1/300-1/500 (contributing to 20-40% of all ASD). 
The prevalence of Asperger syndrome is often estimated to be 0.1-0.5 % [4]. ASDs are 
much more common than previously believed. In the 1960-80´s ASDs were probably 
underreported and a dramatic increase of the ASD prevalence has been reported in 
recent decades – in US from 5 per 10, 000 in 1980 to 1/88 in 2008 as reported in the 
latest survey from Centers for Disease Control [13]. Alterations and widening of 
diagnostic criteria have contributed to more children being diagnosed with ASD. The 
increase of the ASD prevalence may also partially be explained by milder cases with 
ASD, more often diagnosed as Asperger Syndrome or recognition of PDD-NOS, 
whereas the estimated prevalence of autistic disorder has not changed to the same 
extent. In the US study, relatively more children with ASD without ID are currently 
being diagnosed [13]. Several other, additional factors also contribute to this change of 
ASD prevalence rates; increased awareness of ASD among professionals and among 
parents in the general public, rapid expansion of autism diagnostic services, diagnostic 
substitution or diagnostic transfer (children with intellectual disability/learning disorder 
or specific language disorder/ADHD, increasingly diagnosed with ASD) and diagnostic 
accretion (children with ID and children with neurological disorders and syndromes 
also diagnosed with ASD).                               
In a review of prevalence studies by Isaksen et al 2013, the authors discussed that 
reported prevalence rates have been highly variable (4-120 per 10,000 in the period 
1966 to 2012) and that various epidemiological methods influence the estimates. 
During the last decade there has been a stabilization of the ASD prevalence [14]. Three 
recent studies have been published in Sweden. The prevalence for all 2-year-olds in 
Gothenburg (2010) diagnosed with ASD was 8 in 1,000 [12]. The ASD prevalence in 6 
year-olds born in 2002 in Stockholm was 6.2 per 1,000 [15]. In a large register based 
study the overall prevalence of ASD in Stockholm 2007 was 11.5 per 1,000 ranging 
from 6.5 per 1,000 among children aged 4–6years to 14.6 per 1,000 among those 
aged 13–17 years [16].  
 
ASD and gender differences 
 
In previous and recent studies, males are consistently more often diagnosed with ASD. 
Higher sex ratios are found in studies based on clinically ascertained ASD cases and 
lower ratios are found in epidemiological population screening studies. A gender ratio 
of about 3-4:1 is a commonly referred consensus [17-20]. In children with ASD and 
IQs in the normal range, the male to female ratio is often reported to be even higher (6-
15:1) [21], whereas in those with moderate to severe intellectual disability the ratio is 
lower, in the range of 2:1 [17, 22]. Also, other neurodevelopmental disorders (ID, 
ADHD, speech- and language impairment) show a male bias [23-26]. In the Stockholm 
County, a clinical case study estimated the ASD prevalence in 6 year old boys to 10 in 
10, 000 and in girls 2 in 10,000 [15]. In the Stockholm County large register study the 
male: female ratio was overall 2.6:1 and similar for ASD cases with or without ID. 
However, at age 8 years the ratio was 5.1:1 and 1.9:1 at age 18. A delayed ASD 
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diagnosis in females may contribute to the decline in sex ratio at older age [16]. Males 
with ASD, more often than females display externalizing behaviour problems (such as 
aggression and hyperactivity) while females with ASD more often are affected by 
internalizing symptoms such as anxiety and depression [27] and show less stereotype 
and repetitive behaviour [28]. The skewed sex ratio may be explained by under-
ascertainment in females. However, a recent large study of dizygotic twins showed 
that siblings of autistic females had significantly more autistic impairments than 
siblings of males with ASD. The results suggests that female sex protects girls from 
autistic impairments and that girls may require greater familial etiologic load to 
manifest the phenotype [29]. Studies of chromosomal structural variation (CNVs) as 
well as studies of single nucleotide variants (SNVs) have found that more female 
ASD cases than males carry de novo copy number variants and higher rates of SNVs. 
The CNVs identified in females are found to affect more genes than those found in 
males [30-34]. One conclusion is that females are protected from the effects of 
heritable and de-novo ASD risk variants [35]. Higher penetrance of de novo 
mutations in males than females may contribute to the higher prevalence of ASD in 
males [36]. An example of male-biased difference in penetrance was identified in a 
study of inherited SHANK1 mutation where males had high functioning autism while 
female carriers of the same rare mutation displayed anxiety but not ASD [37]. Several 
X-linked genes associated with ID are also found to be ASD risk genes (FMRP, 
MECP2, NLGN3, NLGN4) and sex chromosome aneuploidies are associated with ID 
and increased ASD risk [35]. In 2002, Baron-Cohen formulated the extreme male 
brain theory of autism [38]. Subsequent studies have shown correlation between 
foetal testosterone levels and autistic traits [39] and negative correlation with 
empathizing [40]. Increased levels of testosterone have been reported in females with 
Asperger´s syndrome [41]. Poelmans et al. reported that a large number of ASD 
candidate genes are involved in three major signalling protein networks – one of the 
networks regulating the production and metabolism of the steroid hormones [42].The 
skewed sex ratio reflects true differences in ASD liability and also that female ASD 
phenotypes are not adequately identified and diagnosed [43]. 
 
ASD aetiologies and risk factors - overview 
 
ASDs are the neurodevelopmental disorders with the most clearly documented 
influence of genetic factors [44]. However, despite the convincing genetic basis for 
ASDs, a definite cause remains unknown in most individual cases. Single gene 
disorders and larger chromosomal rearrangements are found in 10-20 % of cases with 
ASD with the genetic methods used today[4].  However, the majority of ASDs are 
probably caused by complex interactions between multiple genes (oligo- and polygenic 
models). Environmental and epigenetic factors modulate gene expression and variation 
in penetrance and expressivity of influential genes add to the broad diversity of clinical 
presentations [45]. Several pre- and perinatal factors have been associated with an 
increased ASD risk, however all these risk factors are also linked to other impairment 
in neurocognitive outcome [46]. In a recent meta-analysis it was demonstrated that 
most perinatal and neonatal factors examined, have shown inconsistent results and the 
preponderance of findings overall have not been statistically significant [47]. Various 
methodologies, diagnostic practises and case selection explain inconsistent results in 
some studies.  In a recent study comparing maternal conditions and perinatal 
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characteristics in cases with ID and cases with ASD with or without ID, only weak 
association was found between perinatal risk factors and ASD without ID [48]. It has 
been suggested by Dodds that among individuals with low genetic ASD 
susceptibility, maternal and some obstetric factors may have an independent role in 
autism aetiology whereas among genetically susceptible children, these factors are of 
less importance [49]. 
 
Genetics: background and human genetic variation 
 
The human haploid genome contains 3 billion base pairs and around 20 500 genes. The 
protein-coding regions, the genes, consist of exons, introns and regulatory elements. On 
average a protein is coded by 10 exons, each including approximately 300 base pairs. 
Transcription is the first stage in the protein synthesis. The gene is transcribed to initial 
RNA (primary transcript), a continuous RNA copy of the gene with both exons and 
introns. The initial mRNA is spliced – the intronic sequences are removed and the 
exonic transcripts are joined together. The mature mRNA is transported to the 
cytoplasm where it acts as the template for translation – the protein synthesis. Through 
the process of alternative splicing, joining the exons in multiple combinations a gene 
may code for multiple proteins. Transcription of DNA is regulated by the degree of 
DNA methylation and histone modification (histones are proteins around which DNA 
is wound to form chromatin). Longrange chromatin interactions also play a role in the 
regulation of the genes [50]. 
 
Figure 1 
 
 
 
The ENCODE project has shown that ∼80 % of the DNA outside the protein-coding 
regions is linked to biochemical functions. The space between the genes is filled with 
enhancers (regulatory DNA elements), promoters (the sites at which DNA´s 
transcription into RNA is initiated) and numerous regions that encode RNA transcripts 
not translated to proteins but with regulatory roles [50].  
DNA 
5´ 
DNA 
3´ 
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It is estimated that more than half of the human genes are expressed in the brain. The 
transcription of these genes varies over time and within different brain areas. The 
greatest regional differences occur during the prenatal development.  
 
Human genomes vary as a result of different DNA changes - mutations. These 
alterations can be classified as sequence or structural variants and usually arise by 
errors is the gametogenesis – the formation (meiosis) of germ-line cells (sperm/egg). 
Mutations also occur during somatic cell division (mitosis), either during 
embryogenesis, in the foetus or later in life.  
More than 50 million different single nucleotide variations (SNVs) are catalogued 
within the human genome (dbSNP database). SNVs that occur in > 1% of the 
population are referred to as Single Nucleotide Polymorphisms (SNPs) and are part of 
the normal variation. A point mutation is defined as substitution of a base pair and may 
occur in coding, regulatory and splicing relevant regions. Indels are insertions and 
deletions of 1-10 000 base pairs. Mutations also include missing or duplicated 
chromosomes (aneuploidy) and structural variations such as translocations, deletions, 
duplications, inversions and complex rearrangements. Other genetic aberrations linked 
to human disease include DNA triplet repeat expansions, imprinting errors, X-
inactivation variants and mosaicisms [51]. More than 120 000 mutations are listed in 
the Human Gene Mutation Database.  
 
The genetic code defines how one of 64 possible triple nucleotide base combinations 
(codons) code for one of twenty specific amino acids, start of protein synthesis or stop 
of translation. A single base substitution within a coding region may lead to an 
unchanged protein due to the existence of more than one codon coding for a specific 
amino acid (silent or synonymous mutation). Alternatively it may substitute one amino 
acid (missense mutation), cause a premature chain termination by introducing a stop 
signalling codon (non-sense mutation) or a frame-shift mutation where all amino acids 
after the mutation are substituted and often resulting in a non-functional protein. 
Frame-shift mutations are often caused by indels that are not multiples of three base 
pairs in length [51].  
 
Mutations may be classified according to their effects on protein function. Reduced 
amount or activity of an encoded protein is defined as loss-of-function. Gain- of-
function mutations lead to an increased amount or activity of the protein. 
 
Copy Number Variants 
 
A recent and important development in human genetics is the discovery of structural 
variations, referred to as Copy Number Variants (CNVs), changing the chromosomal 
architecture and occurring both in phenotypically normal and in diseased subjects. 
Copy Number Variants (CNVs) are defined as submicroscopic structural variations and 
with an abnormal number of copies of a DNA-segment (deletions and duplications) and 
with a size larger than 1000 base pairs. CNVs occur in the normal population and play 
an important role in the human genetic variation. Human genome variation is explained 
by single nucleotide polymorphisms (∼0.1%) and at a structural level where CNVs 
contribute to another ∼0.1% [52]. CNVs have been found to contribute to a greater 
percentage of the total number of base pairs differing between normal genomes than 
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SNPs [53]. On average, each human have > 1000 CNVs, accounting for ∼4 million 
base pairs of difference [52]. CNVs often encompass large regions, affecting more than 
one single gene. CNVs may have great phenotypic impact by altering gene dosage, 
disrupting coding sequences or deregulating gene expression. Several CNVs have been 
found to be associated with diverse neurodevelopmental and psychiatric disorders. 
CNVs may be inherited from one or both parents (transmitted) or occur de novo. A 
CNV may affect one or several genes on the paternal or maternal alleles (heterozygous) 
or, rarely, affect both the paternal and maternal alleles in the corresponding region 
(homozygous). Different CNVs exhibit different penetrance, exemplified by the 
observation of identical CNVs in healthy controls as in affected individuals. Some 
CNVs demonstrate variable expression and can result in several disorders or 
phenotypes (e.g. ASD, ID, schizophrenia and bipolar disorder).  In many complex 
disorders CNVs have identified hot regions with candidate genes and enabled targeted 
DNA sequencing. Many of these ASD associated genes have been associated as risk 
factors for other psychiatric and neurodevelopmental disorders, such as deletion 
22q13.3 (Phelan-McDermid Syndrome) disrupting the SHANK3 gene [54-58], deletion 
2p16.3, disrupting the NRXN1 gene [59-62], deletion 7q35-q36, disrupting the 
CNTNAP2 gene [63-65] and the postsynaptic neuroligins NLGN3 and NLGN4X located 
on the X chromosome [66]. 
 
Genetic technologies 
 
Standard clinical genetic testing in children with ASD has previously included 
conventional karyotyping and molecular testing for Fragile X. In children with ASD 
karyotyping identifies abnormalities in about 2-5% [67, 68] and Fragile X syndrome is 
identified in about 2% [69]. The resolution of conventional karyotyping is limited 
compared to new technologies such as chromosomal microarrays. However, 
karyotyping identifies balanced chromosomal rearrangements, undetectable by micro-
array methods and the contribution of balanced translocations or inversions in ASD is 
approximately 0.4% [70].  
 
Linkage and genome wide association studies 
 
Linkage studies of ASD, using multiplex families, identify shared genetic regions that 
can be linked to the condition between affected members. Alleles close together on the 
same chromosome have a high tendency to be transmitted together as an intact unit. 
Using a large number of genetic markers covering the whole genome, fine mapping of 
a specific region of interest is possible. Linkage studies have identified ASD risk 
conferring regions on all chromosomes but only a few regions have been repeatedly 
replicated. In genome-wide association studies genetic markers are used to compare the 
rates in unrelated affected with matched controls.  The dominant technology that is use 
of high resolution SNP-arrays. To date, the six Genome Wide Association Studies for 
ASD that have been published implicate ∼200 ASD candidate genes [42]. 
 
 
 
 
 
 11 
 
Comparative genomic hybridization  
 
Chromosomal microarrays or array-CGH , enables a whole genome analysis of gains or 
losses of DNA segments. Several different platforms exist, based on the type of DNA-
probes used. The resolution of the method depends on the number of probes and the 
distance between them, increasing the resolution 100-fold compared to conventional 
karyotyping.  
 
Classification and interpretation of Copy Number Variants 
 
To evaluate the clinical significance of rare CNVs, the development of public databases 
have been essential. The Database of Genomic Variants (DGV (http://projects.tcag-
.ca/variation/) catalogues putatively benign CNVs in the general population. Several 
datasets catalogues putatively pathogenic CNVs (e.g. DECIPHER (http://decipher.-
sanger.ac.uk/), SFARI (gene.sfari.org), AutismKB (http://autismkb.cbi.pku.edu.cn). 
 
 
The interpretation of CNVs should be done according to established guidelines [71]. 
CNVs can be classified as pathogenic, with uncertain clinical significance or as benign. 
The size of a CNV must be considered, although even large CNVs can be benign and 
small CNVs can be pathogenic. De novo CNVs and large CNVs > 3-5 Mb are more 
likely to be pathogenic. In addition, the genomic content of a CNV is important. The 
interval may contain gene-rich regions and genes previously reported in association 
with a disorder or encompass a region void of genes. A CNV is categorized as benign if 
it is reported in multiple publications or in databases and the nature of the CNV is well 
characterized or represents a common CNV polymorphism (occurring in > 1% of the 
population). CNVs documented as clinically significant in multiple peer-reviewed 
publications are classified as pathogenic. Inherited CNVs are more difficult to 
classify. The CNV may be pathogenic, but not in the unaffected carrier parent due to 
incomplete penetrance. The carrying parent may have milder subclinical features within 
the spectrum of the disorder due to variable expressivity. Imprinting effects may add to 
the complexity. A second mutation not detected by microarray may be present on the 
corresponding allele or other genetic modifiers (second-hit model) may be present in 
the probands but not in the unaffected parent. Mosaicism for the CNV in the unaffected 
parent may be of importance. An unaffected mother may transmit an X-linked CNV to 
an affected son. In females, phenotypic variation may result due to the possibility of 
skewed X-inactivation [71]. 
 
CNVs of uncertain clinical significance include aberrations, for which at the time 
being, there is insufficient evidence to determine whether it is pathogenic or benign. A 
CNV of uncertain clinical significance may be pathogenic if it encompasses a gene, 
with a function is relevant to the phenotype, even if there are no other reports of similar 
cases [71].  
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Microarray platforms 
 
SNP-array  
 
A SNP array platform has a large number of probes with segments of reference DNA 
(25 Bp oligonucleotide sequences). For each SNP, the array has a matching probe for 
the two possible alleles. The test DNA is purified, digested and labelled with a 
fluorochrome and hybridized to the microarray. DNA fragments containing a SNP 
binds to their allele-specific perfect match probes. After washing the array is scanned 
for fluorescent signals reflecting the DNA copy number and information on the SNP 
alleles in the genotype. Due to linkage disequilibrium, the tendency of chromosomal 
segments to be inherited as blocks (haplotypes), thus single markers (SNPs) can be 
used to predict the genotype of the surrounding region. 
 
Oligonucleotide-array 
 
Oligonucleotide-arrays use sequences sized 60-80 base pairs as probes. Patient-DNA 
and reference DNA are labelled with differently coloured fluorochromes and are 
hybridized to slides with a large number of probes covering the whole genome. The 
slides are scanned and the ratio between the two fluorescence signals is measured. Loss 
of a DNA segment in the test DNA will result in an increased signal from the reference 
DNA and gain will result in an increased signal from the test DNA. By use of 180 000 
or 244 000 oligonucleotide probes it is possible to detect changes in copy number of 
segments sized (30)-50 Kb.  
 
CNV calls can be validated using alternative methods – multiplex ligation-dependent 
probe amplification (MLPA), FISH or quantitative PCR.  
 
Whole exome and whole genome sequencing technologies 
 
By sequencing it is possible to detect variations in a single base pair. In conventional 
sequencing single genes are analysed. During the last years, high-throughput DNA 
sequencing has become faster and much cheaper. Whole exome or whole genome 
sequencing is now available but the analysis of enormous amounts of data is still time 
consuming why it is difficult to use the methods in large cohorts. However, by the use 
of this methodology it is possible to analyse 100-200 selected genes (panels) in larger 
cohorts.  
 
Genetics and heritability in ASD 
 
Albeit the robust evidence for genetic factors in ASD, a specific genetic aberration can 
be detected in less than 20-30% of individuals with ASD with the current available 
technologies. The complex patterns of inheritance display an extreme heterogeneity and 
various distinctive genetic models contribute to explain the genetic background of 
subsets of individuals with ASD. Despite the high heritability most genetic findings 
linked to ASD causality are de novo genetic aberrations, i.e. not inherited. 
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Familial aggregation, twin and adoption studies clearly indicate that genetic factors 
highly contribute to the risk for ASD. In the last decade a large number of studies on 
ASD and autistic traits in twins have been published. Heritability (defined as how much 
of the variance is explained by shared genetic factors) may be calculated comparing the 
concordance in monozygotic (MZ), identical, and dizygotic (DZ), fraternal twins. Twin 
studies are also used to estimate the degree of environmental influences and whether 
the environmental influences are shared or non-shared.  
 
Twin studies 
 
 Early twin studies estimated the autism concordance rate in identical twins 
(monozygotic=MZ) at 36-91% and in fraternal twins (dizygotic=DZ) at 0%. [72-74]. 
More recent studies have replicated similar high ASD concordance in MZ twins. 
However, they report substantially higher concordance in DZ twins than in earlier 
studies. The heritability estimates in the earlier studies ranges between 60-90% [75-77]. 
The median values for broad ASD concordance were 88% for MZ twins and 31% for 
DZ twins in three new studies reviewed by Ronald and Hoekstra [78]. Hallmayer et al. 
(2011) reported conflicting results in their study of 192 twin pairs. The concordance for 
strict autism in male MZ twins was 0.58 vs. 0.21 in DZ twins and in female MZ twins; 
the concordance was 0.60 vs. 0.27 for DZ twins. The authors concluded that a) earlier 
studies have underestimated the concordance in DZ twins b) susceptibility to ASD has 
a moderate genetic heritability and a substantial shared twin environment component 
[79]. No twin study has shown complete concordance in MZ twins and prenatal/early 
postnatal epigenetic, stochastic and environmental factors impact susceptibility to 
ASDs.  
Autistics like traits have been shown to occur in a smooth normal distribution in the 
general population to the clinical extremes [80, 81]. The concordance rates for autistic 
traits in twins in the general population were estimated in a UK study. The results 
showed high heritability; concordance for same-sex MZ males was 0.78 vs. 0.26 in 
DZ same-sex males. Thus, heritability for autistic traits in males was 72% and 53% in 
females. The study indicated evidence of similar aetiology across normal variation 
and the extreme scoring groups [82]. A nationwide twin study, by Lundström et al. 
demonstrated an aetiological similarity between ASD and autistic like traits in the 
normal variation and suggested that ASD and autistic like traits are aetiologically 
linked [83]. In addition, studies have shown increased rates of a broad variety of 
neurodevelopmental disorders in ASD twins (ADHD, developmental motor disorder 
and tic disorder [75].  
 
Sibling studies 
 
The recurrence risk for siblings has probably been underestimated in earlier studies 
with estimates between 3 and 10 %. Constantino et al, 2010, reported a recurrence risk 
for a traditionally defined ASD to be 10.9 % and that another 20 % of siblings had a 
history of language delay, one half off whom exhibited autistic qualities of speech [84]. 
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In a baby sibling study, Ozonoff et al. reported an overall recurrence frequency of 18.7 
% (26 % for infant sibling boys and 9% for infant sibling girls) [85]. Three recent 
studies have estimated roughly a 25-fold increased risk for ASD in siblings [77, 84, 
85]. 
 
Genetic findings in ASD - overview 
 
In about 10 % of individuals with ASD a monogenic disorder can be identified. Most 
common are Fragile X syndrome, tuberous sclerosis and Rett syndrome. There are 
numerous other genetic disorders where a subset of affected individuals also present 
with co-existing ASD; Angelman syndrome, Neurofibromatosis type I, CHARGE 
syndrome, Moebius syndrome, Cohen syndrome, Smith-Lemli-Opitz syndrome, 
Timothy syndrome, Soto’s syndrome and 22q11 deletion syndrome. ASD is 
additionally found in individuals with larger chromosomal aberrations such as trisomy 
21, Turner syndrome and Klinefelter syndrome). 
 
Fragile X syndrome 
 
Fragile X syndrome (FXS) affects about 1/4000 males and 1/6000 females. FXS is the 
second most common genetic cause of ID after trisomy 21. About 25% of FXS males 
and 6% of FXS females have autistic features [4]. In individuals with ASD, FXS is 
found in about 2% [69]. The molecular basis of FXS is an abnormal number of 
trinucleotide repeats (CGG sequences) in the FMR1 gene on the X chromosome 
(Xq27.3). Normally there is an average of 30 tandem repeats and individuals with 
Fragile X have more than 200 repeats [4]. The excessive number of repeats produce 
abnormal methylation of the FMR1 gene and transcription silencing followed by 
decreased levels of Fragile X Mental Retardation Protein (FMRP). The decreased 
FMRP levels affects important signalling pathways in the brain and interferes with 
dendritic maturation and synaptic plasticity.  
 
 
Tuberous sclerosis 
 
Tuberous sclerosis complex (TSC) affects about 1/6 000. Inactivating mutation in 
either the TSC-1 gene, located on chromosome 9q34 or the TSC-2 gene, located on 
chromosome 16p13.3, causes TSC. The neurological manifestations of TSC include 
infantile spasms, intractable epilepsy, cognitive disabilities, and autism. Half of the 
children with TSC have ID and 25-40 % have autistic features [86]. In individuals with 
ASD, TSC is found in 1-3% [4]. Children with TSC and autism display more global 
cognitive impairment than those with TSC without autistic features. The disorder is 
characterized by the presence of hamartomas (tumor-like lesions) in multiple organs, 
including the brain. Epilepsy is common as well as a wide range of behavioural 
problems. Early onset epilepsy and infantile spasms have been associated with 
significant risk for ID and ASD [87].  
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Rett syndrome 
 
Rett syndrome is a genetic disorder affecting about 1/10 000 girls. Among girls with 
ASD, Rett syndrome has been reported in about 3%. Rett syndrome is caused by 
mutations in the MECP2 gene on chromosome region Xq28. The gene encodes for 
MeCP2 (Methyl-CpG-binding protein) that affects the transcription of a large number 
of genes. Loss (and gain) of function of MeCP2 leads to a severe clinical condition that 
present in different variants. Girls with the most typical Rett variant have an apparently 
normal development during the first 6-18 months. A loss of function/regression occurs 
with impairment of language and social interaction. There is partial or complete loss of 
spoken language and loss of purposeful hand skills. Other main criteria include gait 
abnormalities and stereotypic, often characteristic hand movements. Many have a 
subnormal head growth resulting in microcephaly. Epilepsy is very common (∼60%), 
with onset about 2-3 years of age and with an improvement of seizures after puberty 
[88].  
 
ASD and Copy Number Variants 
 
Microarray studies have demonstrated increased rates of CNVs in individuals with 
ASD (5-15 %) compared to healthy controls (1-2%) [30, 32, 89-96]. These increased 
rates occur both as sporadic (de novo) mutations and as inherited CNVs, often from an 
apparently healthy parent. An overall increased burden of large CNVs has also been 
documented in individuals with intellectual disability, schizophrenia and bipolar 
disorder [52]. CNVs in individuals with ASD are more numerous and contain more 
genes than compared to controls. Females with ASD, compared to males have more 
and larger CNVs. In individuals with ASD in combination with ID and/or dysmorphic 
features more CNVs are detected.  
 
ASD and coding sequence variants 
 
Sequencing of candidate genes has implicated a large number of mutations that appears 
to be sufficient to cause ASD. In 4-8 % of individuals with ASD, rare highly penetrant 
mutations (Single Nucleotide Variants) can be identified [33, 34, 97, 98]. The average 
rate of de novo coding-sequence variants, in these studies did not significantly differ 
between individuals with ASD compared to unaffected siblings and controls. However, 
a statistically significant difference was found when the analysis was restricted to genes 
expressed in the brain [99]. Approximately 65 ASD causing mutations were identified 
in an exome sequencing study by Iossifov et al, and the authors estimate 350-400 
autism susceptibility genes. Females with ASD have been found to carry more gene 
disrupting mutations [100]. De novo SNVs as well as de novo CNVs often combine 
with other risk factors [33]. Higher rates of de novo mutations in older fathers has 
recently been documented [101]. Lim et al reported that a minor fraction of ASD cases 
is explained by double loss of gene function caused by inherited homozygous and 
compound heterozygous point mutations in autosomes and in the X chromosome. The 
authors suggested that this enrichment of double loss of function variants contributes to 
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3% of ASD cases and to another 1.7% in males [102].  
 
ASD and common polymorphisms  
 
In multiplex families, inherited CNVs and SNVs, as well as common risk variants with 
low effect size contribute to ASD susceptibility. Klei et al, estimated that common 
genetic polymorphism exerts substantial additive genetic effects on ASD liability and 
explains at least 60 % of the variance in ASD cases from multiplex families and that a 
myriad of common variants of very small effect impacts ASD liability [103]. However, 
common polymorphisms have been difficult to identify and replicate. The relative risk 
conferred by these loci is small [104, 105]. Devlin and Scherer summarized the latest 
Genome Wide Association Studies, searching for SNPs association to ASD and 
concluded that no common variant have substantial impact on risk (Odds Ratio > 1.2) 
but many common variants may have modest impact [68]. 
 
ASD and neurometabolic disorders  
 
Neurometabolic disorders in individuals with ASD are rare and metabolic screening is 
often negative. Most new-born children in Sweden are enrolled in the neonatal 
screening for selected metabolic disorders, of which some have been associated to 
intellectual disability and ASD (e.g. phenylketonuria and [106] homocystinuria [107]). 
Several studies have reported low diagnostic yield of metabolic testing in children with 
ASD [107-111]. Selective testing should be performed when there are additional 
clinical symptoms, such as a history of lethargy, cyclic vomiting, early seizures, 
dysmorphisms, mental retardation, or regression and if the neonatal screening was not 
performed [112]. Neurometabolic disorders that have been implied in autistic 
phenotypes include disorders of purine metabolism, a group of creatine deficiency and 
creatine transport disorders, biotinidase deficiency, cerebral folate deficiency, succinic 
semialdehyde dehydrogenase deficiency, Sanfilippo syndrome and Smith-Lemli-Opitz 
syndrome.  
 
ASD and mitochondrial disorders  
 
Mitochondrial dysfunction measured as different levels of biomarkers compared to 
healthy controls have been demonstrated in individuals with ASD [113]. Biomarkers 
that could indicate mitochondrial dysfunction include lactate, pyruvate, ubiquinone and 
carnitine. In a recent meta-analysis by Rossignol and Frye, the authors conclude that the 
prevalence of mitochondrial dysfunction was 5% in children with ASD vs. ∼0.01% in 
the general population [114]. Mutations in mitochondrial DNA associated with 
mitochondrial function have been identified in isolated cases of ASD [115-119]. They 
include mitochondrial DNA mutations, mtDNA depletions/deletions and a few cases 
with POLG mutations. Children with ASD and mitochondrial disorder may have a 
history of regression, sometimes triggered by fever and clinical symptoms could 
include muscular hypotonia, ptosis, dysarthria and epilepsy. A recent study of a large 
cohort of individuals with ASD, found no evidence to suggest a major role for 
mitochondrial DNA variation in ASD susceptibility [120]. The biomarkers indicating 
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mitochondrial dysfunctions in individuals with ASD appear to be secondary to the 
underlying pathophysiology in most cases [121]. In summary, truly mitochondrial 
forms of ASD are rare [122]. 
 
 
ASD and prenatal risk factors                
 
Pre-conception risk factors include advanced maternal and paternal age, autoimmune 
disorders in the parent, season of conception and birth, birth order (primiparous 
woman), parental socioeconomic status and fertility treatments. Maternal overweight at 
birth has also been found to be an ASD risk factor [49]. Prenatal environmental risk 
factors include multiple births, threatening abortion, bleeding during pregnancy, and 
intrauterine exposure to maternal psychoactive medication and alcohol. Preeclampsia 
has been shown to be an ASD risk factor in some studies [123, 124] but did not reach 
significance in the meta-analysis by Gardener [47], neither in the review by Guinchat 
[125]. Infectious and immune disturbances during the prenatal period have emerged 
as potentially important ASD risk factors. Vitamin D deficiency in early life affects 
neuronal differentiation and axonal connectivity and is increasingly being associated 
with a number of neurologic (e.g. multiple sclerosis) and psychiatric conditions 
(schizophrenia). Observation of increased incidence of a disorder in higher latitudes, in 
individuals born during winter/spring and in the offspring of dark skinned mothers 
could be indirect indications of risk linked to low vitamin D levels. Some studies have 
reported such associations with ASD but other studies have not.  At present, no study 
has measured low maternal vitamin D levels during pregnancy and demonstrated an 
increased risk for ASD in the offspring [126]. Prospective longitudinal studies with 
larger samples are needed. 
 
Parental age 
 
Advanced paternal [127-129] and maternal age [127, 130] has been associated with an 
increased risk for ASD in the offspring. Interestingly, a recent study showed an 
increased risk of autism linked to advanced age in grandparents [131]. Advanced age in 
fathers [132, 133] and grandparents [134] has also been associated with schizophrenia 
and advanced paternal age has been associated with increased risk for intellectual 
disability [135]. In ASD and in ID it has been shown that risk conferring de novo 
mutations more often are of paternal origin [33, 34, 98, 100, 135] and a higher rate of 
de novo mutations in older fathers has recently been found using whole genome 
sequencing [101]. It has been speculated that in the ASD cases, advanced paternal age at 
the time of the birth of the first child could reflect a broader ASD phenotype [136]. 
Advanced maternal age has also been associated as a risk factor for numerical 
chromosomal aberrations (aneuploidy), structural chromosomal aberrations (increased 
burden of CNVs) and congenital malformations [137, 138].  
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Migrational status 
 
Parental migration status and increased risk for ASD has been described in European 
studies, mostly from Nordic Countries. In UK, children to mothers of Caribbean, 
African and Asian origin were found to have increased risk for ASD [139]. In the 
Swedish study by Haglund et al. maternal birth outside the Nordic Countries was 
associated with autism but not with Asperger syndrome [140]. In a Swedish register 
study by Magnusson et al., an increased risk for ASD in combination with ID was 
observed and the highest risk was found when parents migrated from regions with a 
low human development index, and peaked when migration occurred around 
pregnancy [141]. An increased prevalence of ASD and ID has been documented in 
children of Somali origin in Stockholm County [142]. In the review by Guinchat et al. 
(2012), having a mother born outside Europe, North America or Australia was 
consistently associated with ASD risk [125]. 
Autoimmune disorders 
 
Epidemiological studies have shown that the prevalence of autoimmune disorders (e.g. 
maternal type 1 diabetes, rheumatoid arthritis, ulcerative colitis and celiac disease) is 
elevated in families of individuals diagnosed with ASD [143-145]. The risk conferring 
disorders vary between the different studies. In a register study by Keil et al., a 50% 
increased risk for ASD in the offspring was observed if any parent (maternal OR =1.6 
and paternal OR =1.4) had an autoimmune disorder [143]. Recent studies have 
identified the presence of maternal autoantibodies that react against foetal brain 
proteins in mothers of ASD children [146, 147]. Maternal autoimmune disorders have 
been linked to an increased risk for a wide range of adverse neurodevelopmental 
outcomes [148]. One pathophysiological pathway that has been suggested is that 
mothers with autoimmune disorders have an increased risk for gestational preeclampsia 
that may impair the foetal brain development [148]. 
 
Maternal infections during pregnancy 
 
Several intrauterine infections have been associated with adverse neurological and 
cognitive outcome and some evidence also suggests that maternal infection and 
immune dysfunction may be associated with autism. Congenital rubella [149] and 
cytomegalovirus [150, 151] have been linked to ASD. The meta-analysis by Gardener 
indicated that intrauterine infections confer a small but significant increased risk for 
ASD [47]. Maternal influenza infection during pregnancy and prolonged episodes of 
fever was shown to increase the risk for ASD, however the authors concluded that 
mild infections, febrile episodes, or use of antibiotics during pregnancy were not 
strong risk factors for ASD [152]. A Swedish register study found no associations 
between maternal prenatal infections or infection-related variables and autistic 
disorders [123] and in the review by Guinchat, maternal infections during pregnancy 
did not reach significantly increased adjusted odds ratios [125]. 
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Intrauterine exposure 
 
Children exposed in utero to the antiepileptic drug sodium valproate have been found to 
have an increased prevalence of neurodevelopmental disorders, including ASD [153, 
154]. Conflicting results have been published on alcohol exposure and increased risk 
for ASD. In the meta-analysis by Gardener, maternal alcohol consumption during 
pregnancy was not associated to ASD and no association was found between average 
alcohol consumption and ASD in a Danish study [155]. In two Swedish studies, 9-13 % 
of children whose mothers abused alcohol in pregnancy had ASD [156, 157]. Other 
teratogen substances that have been linked to ASD are thalidomide and misoprostol, 
both inducing congenital malformation and neurodevelopmental impairment [158].   In 
the study by Gardener, a meta-analysis of the two studies that looked specifically at 
psychiatric medication use during pregnancy, the analyses suggested a significant 
positive association with the risk of autism [47]. Similar findings were reported by 
Dodds et al., where maternal use of prescribed psychoactive drugs were more often 
reported [49]. A 2-fold increased risk of ASD was associated with treatment with 
selective serotonin reuptake inhibitors by the mother in a Californian study [159]. In a 
Swedish register study, similar findings were recently reported. A history of maternal 
depression and antenatal use of antidepressants was associated with an increased risk 
of ASDs in the offspring, the increased risk confined to ASD without ID [160]. 
 
Parental psychiatric history 
 
Parental psychiatric history has been associated with increased risk for ASD in the 
offspring in clinical [161-163] and epidemiological [164-166] studies. In mothers (but 
not in fathers) of children with ASD, depression and personality disorders were found 
to be more common than in mothers of typically developing children [164]. A recent 
Australian study identified maternal bipolar disorder as a risk factor for ASD. This 
study showed that maternal schizophrenia/bipolar disorder/unipolar depression also 
was associated with an increased risk for ID and rare congenital syndromes in the 
offspring [167]. In a recent Finnish, population-based case-control study by Jokiranta et 
al., the authors examined associations between parental psychiatric history (based on 
in-patient records) and risk for ASD in offspring. The study calculated the associations 
with the three ASD sub-groups (autistic disorder, PDD-NOS and Asperger´s 
syndrome). Total ASD was associated with maternal schizophrenia, affective and 
anxiety disorders. Autistic disorder was associated with maternal depression but not 
with PDD-NOS or Asperger´s syndrome. However, PDD-NOS and Asperger´s was 
associated with maternal schizophrenia, affective and anxiety disorders. Maternal 
depression has been identified as a risk factor for ASD in previous studies. In the study 
by Jokiranta, also paternal affective disorders were associated with a 2-fold risk of ASD 
in the offspring, suggesting a shared genetic background for ASD and affective 
disorders.  Paternal schizophrenia was also associated with autistic disorder. An 
adjusted three-fold increase of ASD risk was found if both parents had a psychiatric 
disorder. Interestingly, strongest association was shown between parental psychiatric 
disorders and PDD-NOS [168]. As mentioned before, an association between maternal 
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use of anti-depressants during pregnancy and ASD risk in the offspring has been 
identified [159, 160]. 
 
Peri- and neonatal risk factors 
 
Several perinatal and neonatal risk factors are associated with neurodevelopmental 
disorders including cerebral palsy. Multiple births, preterm birth, low birth weight, 
small for gestational age, breech presentation and caesarean section has have all been 
found to confer ASD risk. Scheduled caesarean section has been identified as an ASD 
risk factor in several studies [169-172]. Guinchat concludes that during the perinatal 
period, the predominant risk factors were preterm birth, breech presentation and 
planned caesarean section. All the documented adjusted odds ratios were between 1.3 
and 2.8 [125]. Other neonatal ASD risk factors, that have been reproduced, are low 
Apgar score, neonatal encephalopathy, congenital malformations and 
hyperbilirubinaemia. 
 
Low birth weight and preterm birth 
 
Low birth weight and preterm birth contribute to ASD risk. Pinto-Martin et al. 
estimated the ASD prevalence in children with birth weight less than 2000 g to be five 
times the population prevalence [173]. Losh et al, comparing autism-discordant twin 
pairs found that the twins with lower birth weights were three times more likely to meet 
criteria for ASD than the heavier twins [174]. A foetal growth that was less than two 
standard deviations below the mean increased the risk of ASD, both with and without 
ID [175]. Children born extremely preterm have higher prevalence of cognitive and 
attention deficits. In a recent Swedish study of children born < 27 gestational weeks, 
11.3 % had moderate or severe cognitive disability vs. 0.3 % in controls at 2.5 years 
[176]. Screening children with birth-weight < 1500 g for ASD has indicated that a 
high proportion (10-25%) have autistic features [177-179]. However, the 
interpretation of these results must be cautious as motor and sensory impairments 
lead to high rates of false-positive screens [180]. In a UK study of children born < 26 
gestational weeks, 16 % screened positive but only 8 % were diagnosed with ASD 
[181]. Buchmayer et al. discussed that the risk of autistic disorders in premature 
children may be mediated by prenatal and neonatal complications [123].  
 
 
ASD and co-existing conditions  
 
The most common co-existing disorders in children with ASD are intellectual 
disability, ADHD, epilepsy and psychiatric disorders. Furthermore diverse behavioural 
problems, sensory abnormalities, delays and deficits in motor functions and birth 
defects are common co-existing conditions. Sleep- and feeding problems are often 
present as well as gastrointestinal symptoms.  
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Intellectual disability and ASD 
 
In children with autistic disorder about 50-70% are also diagnosed with ID, containing 
the full spectrum of mild to profound ID [1-3]. Including all types of ASD at age 9-12 
years, 34% had intellectual disability in a Swedish twin study [75]. Intellectual 
disability is found in 1-3% of the childhood population and a large proportion has a 
genetic aetiology. The prevalence of autism increases with the severity of the ID. In 
adults with ID (18-87 years old) Saemundsen reported a 21% prevalence of autism 
[182]. Similar to ASD, there is a skewed sex ratio with more males having ID [183]. X-
linked mental retardation affecting only males contributes to the skewed ratio. Strong 
evidence for great overlap between ASD and ID has emerged from genetic studies. In 
the review by Betancur, 103 gene variants found to be associated with ASD, were all 
likewise associated with ID [184]. Neale et al. stated that most de novo CNVs found in 
association with autism, often were linked to “a broad range of conditions including ID, 
epilepsy and schizophrenia” [33]. In individuals with ASD and intellectual functioning 
within the normal range, it is likely that oligo- and polygenic risk variants play a more 
dominant role compared to individuals with ASD and ID, where a larger proportion 
exhibit detectable genetic risk variants. Current genetic findings suggest that many 
single gene variants and larger structural chromosomal aberrations contribute to 
multiple phenotypes caused by pleiotropic effects of the genes involved [46].  
 
ADHD and ASD 
 
ADHD as well as ASD, is a highly heritable disorder. Simonoff et al. reported an 
ADHD prevalence of 28 % in 10-14 year old children with ASD [185]. Hofvander et 
al. reported an ADHD prevalence of 43% in adults with ASD without ID [186]. A 
higher than expected rate of autistic symptoms in children with ADHD was shown in a 
large multicentre study [187]. In the twin study by Lichtenstein et al., 51% of children 
with ASD (excluding cases with syndromic ASD) also met criteria for ADHD. 
Concordance for ADHD in MZ twins with ASD was 44% vs. 15% in DZ twins. The 
result suggests that a large part of the genetic susceptibility for ASD was shared with 
ADHD. The authors concluded that different neuropsychiatric disorders seem to have a 
common genetic aetiology [75].  
 
Epilepsy and ASD 
 
Childhood epilepsy, defined as recurrent unprovoked seizures, can be regarded as a 
spectrum of numerous disorders with extensive clinical and aetiological heterogeneity 
[188]. The overall prevalence of childhood epilepsy is 0,5-0.7% [189, 190]. The 
cumulative epilepsy incidence is likely about 1.2-2% at age 25 years [191]. Childhood 
epilepsies may be caused by several pre- peri - and postnatal conditions, such as genetic 
disorders, congenital CNS-malformations, intrauterine infections, neonatal 
encephalopathy, cerebrovascular events, head trauma, brain tumours, hypoxia and 
numerous neurometabolic disorders. With novel high-resolution SNP-assays, array-
CGH and high-throughput sequencing technologies an increasing number of genetic 
causes are identified.  
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Among epilepsies with a genetic underpinning most cases are sporadic with no family 
history and a minor fraction is classified within the familial or inherited epilepsy group. 
In this group the inheritance exhibits complex patterns and few susceptibility genes 
have been identified [192]. De novo sequence mutations contribute to epilepsy 
pathogenesis and exome sequencing has revealed high rates of de novo mutations in 
children with Dravet syndrome and other infantile epileptic encephalopathies. A subset 
of CNVs linked to ID, schizophrenia and ASD have also been associated with epilepsy 
(e.g. deletion 16p13.11 and deletion 15q13.3) [192]. CNVs may be recurrent (inherited 
or de novo) and confer risk for common epilepsy and non-recurrent large CNVs that 
arise de novo play a role in the epileptic encephalopathies.  
 
The rate of epilepsy in children with ASD is significantly higher than in typically 
developing children. The epilepsy prevalence in children with ASD has been estimated 
between 5-46% [193, 194]. The rates of epilepsy in individuals with ASD increase with 
age. A recent, large epidemiological study by Viscidi et al. established that the 
prevalence of epilepsy in children with ASD at age 2-17 years was approximately 12%, 
and by adolescence approximately 26% [195]. Many prior studies have found that 
epilepsy in children with ASD is strongly associated with intellectual disability. In 
children with epilepsy, approximately 25% have ID [196]. In the meta-analysis by 
Amiet et al., a pooled frequency of epilepsy was 21.4% in cases with autism and ID. 
The rate of epilepsy in subjects with autism without cognitive impairment was 8% 
[197]. Similar results was reported by Woolfenden et al., in their meta-analysis 1.8% 
had epilepsy at age under 12 years (majority did not have co-existing ID) and 23.7% in 
cases > 12 years (majority ASD and ID) [198] . In the Viscidi study, age and cognitive 
ability was independently associated with epilepsy. For one standard deviation increase 
in IQ, the odds of having epilepsy decreased by 47% [195]. In children with epilepsy 
and IQ > 80, the prevalence of ASD was estimated to be 2% [199]. ASD and epilepsy 
have also been associated with female gender [200] and a history of regression but 
inconsistent results have been found. When adjusting for IQ, female gender and a 
history of regression was not associated with epilepsy in the study by Viscidi [195].  
 
Early onset epilepsy has been associated with increased risk of ID and ASD. 
Saemundsen et al. found that 14 % of children with epilepsy onset in the first year of 
life developed autism. In children with infantile spasms, the risk for ASD was 46% and 
in children with more severe structural brain disorder (hypoxic ischemic 
encephalopathy, cortical dysplasia, tuberous sclerosis) 69% were found to have ASD 
[87].  In children with active epilepsy, ASD have been found in 37% [201]. Brooks-
Kayal have proposed abnormal synaptic plasticity producing an imbalance between 
excitation and inhibition, a shared finding in Fragile X syndrome, Rett syndrome, 
tuberous sclerosis, mutations in the CDKL5 gene and mutations of the neuroligin genes 
to explain the link between ASD and epilepsy [202]. The association between autism, 
intellectual disability and epilepsy suggests that these are concurrent symptoms of an 
underlying brain dysfunction and shared genetic pathways rather than being comorbid 
associated separate disorders [46].  
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Sensory abnormalities 
 
Abnormal responses to sensory stimuli are common in children with ASD. These 
symptoms have been reported to distinguish ASD from other developmental delays 
[203]. Hyper- or hyporeactivity to sensory input or unusual interest in sensory aspects 
of the environment have been included in DSM-5 ASD criteria. Klintwall et al. 
reported that that sensory abnormalities differed among children with autism 
spectrum disorders according to autistic subgroups and that sensory/perceptual 
abnormalities were most frequent in the subgroups with nuclear autism without 
learning difficulties and in the Asperger syndrome group [204]. 
 
Motor impairments 
 
In many children with ASD there are co-existing impairments in fine- and gross motor 
performance. Motor impairments include both developmental delays and deficits. 
Several studies have documented delays in achieving motor milestones, such as sitting 
unsupported and walking independently. Children may have clumsiness and dyspraxia 
(impairments in skilled movements) and gait abnormalities (e.g. toe-walking) [205]. In 
a meta-analysis by Fournier et al., the authors concluded that substantial motor 
coordination deficits are present across ASD subtypes, persist over time and are 
cardinal features of ASD [206]. 
 
Birth defects and ASD 
 
A high frequency of minor malformations has been reported in individuals with ASD 
[207]. Also birth defects are more often found in children with ASD compared to the 
general population. Schendel et al. reported a 6% rate of birth defects in cases with 
ASD, compared to 3.2% in controls and that a skewed sex ratio with a male 
preponderance was found in children with ASD and birth defects. There was an 
association with more birth defects in children with ASD in combination with ID [208]. 
 
 
Early identification and screening 
 
There is general agreement that ASDs should be identified as early in life as possible, 
with a view to ensuring that intervention can start as quickly as possible. Because of the 
extremely heterogeneous aetiology of ASD, with varying degrees of associated brain 
dysfunction, time of identification will probably have to vary. Identifying atypical 
behaviours in infant siblings of children with autism has been done in several studies 
displaying the heterogeneity of onset time as well as the wide variation in presenting 
symptoms [46].  
 
Screening instruments, (e.g. Modified Checklist for Autism in Toddlers (M-CHAT)) 
for early identification of ASD have been developed [209, 210]. In Gothenburg, 
Sweden a general population screening at child health centres has been conducted for 
children at the age of 2.5 years. The screening instruments used were the M-CHAT 
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completed with a short observation of the child´s joint attention. The positive predictive 
value of the screening method was found to be 90%. [211]. Similar results were 
reported from a Flemish study using a screening instrument at day-care centres [212]. 
Unspecific symptoms during infancy such as sleeping, crying or feeding difficulties 
have been reported in children later diagnosed with ASD [213]. Despite behavioural 
markers being identified within the first year of life, the current average age of 
clinical diagnosis of ASD remains at approximately 3 years or older [214]. 
 
 
Early intervention programs 
 
There is now a number of early intervention programs available more or less 
specifically focused on autism. One major intervention model is based on applied 
behaviour analysis (ABA), founded on basic principles of learning, motivation and 
positive reinforcement [215]. Another major model is Treatment and Education of 
Autistic and related Communication handicapped CHildren (TEACCH) emphasizing 
visual work systems, positive routines and structured teaching [216]. In a meta-analysis 
by Eldevik et al that involved nine controlled studies measuring the efficacy of Early 
Intensive Behavioral Intervention (EIBI), a standardized mean difference effect size for 
two available outcome measures, change in full-scale intelligence and/or adaptive 
behaviour composite, was demonstrated [217]. Similar results were reported by Virués-
Ortega [218]. Most authors agree that EIBI result in some improved outcomes in the 
short- and intermediate-term perspective [219-224]. However, these studies have 
demonstrated considerable variability in outcome with low initial IQ repeatedly 
demonstrated to contribute to a less favourable outcome [225]. It is important to 
remember that in many of these studies children with co-existing genetic and medical 
disorders, such as epilepsy and severe ID, have been excluded [222, 225-227]. Recent 
reviews, conclude that early intensive behavioural intervention is likely to be beneficial 
[228] but that the evidence regarding efficacy is still limited due to the lack of 
randomized control studies (RCT). Additional studies using RCT research designs, 
also considering the broad aetiological panorama are needed to make stronger 
conclusions about the effects of EIBI for children with ASD [229]. 
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2 AIMS OF THE THESIS 
 
Study I 
 
To characterize and to increase the awareness of the striking variety of co-existing 
developmental disorders in children with early diagnoses of autism spectrum disorder 
in a population-based group of 208 preschool children. 
 
Study II 
 
To analyse certain prenatal risk factors in a representative group of preschool children 
with early diagnoses of autism spectrum disorders and to investigate gender 
distribution of neurodevelopmental and psychiatric conditions in their first-degree 
relatives. 
  
Study III 
 
To explore the frequency of genetic and other medical conditions, including epilepsy, 
in a representative group of preschool children with early diagnosis of autism 
spectrum disorders and to relate outcome to co-existing medical findings. 
 
Study IV 
 
To investigate the frequency of copy number variants using chromosomal microarrays 
in a representative group of preschool children with early diagnosed autism spectrum 
disorders. 
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3 PARTICIPANTS  
 
Study I  
 
The group in study I included 208 children, (176 boys and 32 girls, sex ratio 5.5:1) 
20–54-month-old when referred to a specialized habilitation centre with a diagnosis 
of ASD. They were drawn from a population-based group of 313 children (born 
2002–2006) with ASD diagnoses in Stockholm County, a region with approximately 
28,000 births per year. Of these 313 children, 288 had been referred for early 
intervention to a specialized habilitation centre for preschool children with ASD.  
Twenty-five children of the 313 children with more severe medical conditions and 
syndromes in combination with ASD had been referred to general habilitation centres 
due to more complex medical needs. At these centres, no specific ASD interventions 
were provided. This group was not included in any of the studies. Of the 288 
children, 24 had been referred to the centre prior to study start and could not be 
included. Of the remaining 264 children, 37 parents declined participation, 15 parents 
could not communicate in either Swedish or English, two families moved abroad and 
another two children had been referred back to general habilitation centres due to 
their complex medical needs. No exclusion of children with ASD and identified 
medical conditions/or significant ID was done. Of the total group of 208 children, 64 
(31%) had been referred before the age of 36 months, 83 (40 %) between 37-48 
months and 61 (29%) between the ages of 49–54 months. 
 
Study II 
 
In study II, 206 of the 208 children were included in a) the register study and b) the 
parental interviews. Two children were adopted why pre- and perinatal data were 
unavailable. 
 
Study III 
 
Of the 208 children, 198 participated in the intervention outcome follow-up study 
after two years. Complete cognitive data was obtained in 196, and data regarding type 
of ASD in 197 children. Vineland Adaptive Behavior Scale-II data (VABS-II) were 
available in 192 children.  
 
Study IV 
 
Parents of the 208 children with early diagnosis of autism spectrum disorder were 
recommended genetic testing with chromosomal micro-array (CMA) and testing for 
Fragile X. CMA was performed in 162 children.  
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Figure 2 
Flow-sheet participants in the study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
All ASD birth years 2002-2006
n=313 
Autism Center for Young Children
n=288
General Habilitation Center 
n=25
Excluded before the study start 
n=24
Invited to the study 
n=264 
General Habilitation Center 
n=2
Parental decline 
n=37
Moved abroad 
n=2
Excluded – language problems 
n=15
Included in the study 
n=208
No medical condition identified
n=170
Any medical/genetic condition 
including array-CGH 
n=38
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4 METHODS 
 
Study I 
 
The clinical research team consisted of four physicians (two neuropaediatricians, one 
paediatrician, and one child psychiatrist), two clinical psychologists and two speech 
and language pathologists. 
 
Paediatric clinical examination  
 
All children were examined by one of the physicians who also interviewed at least 
one parent, evaluated all available medical reports and collected data from the 
maternity and obstetric units. Data regarding developmental milestones according to 
the Swedish Child Health Care Centers protocol were collected. 
 
PARIS schedule 
 
The parental interviews followed a structured protocol, the PARIS schedule (Paris 
Autism Research International Sib pair Study), including the DSM-IV diagnostic 
checklist, detailed family history interview, a variety of clinical developmental data, 
symptoms and signs and a schedule for brief neuromotor examination of the child 
[230]. 
  
Vineland Adaptive Behavior Scales-II (VABS-II) 
 
An interview was performed according to the Vineland Adaptive Behavior Scales-II 
[231]. VABS-II is a valid and often used outcome measure of adaptive skills in 
children with ASDs [223, 226]. 
 
Autistic Behavior Checklist (ABC) 
 
The Autistic Behavior Checklist, a questionnaire pertaining to core symptoms of 
autism, was used as parent interview while observing the child during the research 
paediatric examination [232].  
 
Cognitive test data 
 
The research psychologists scrutinized psychological records from the first referring 
assessment team, with a view to establishing the level of overall cognitive function of 
the child at referral. For some children a complete cognitive test had not been 
possible to perform according to the referring psychologist and in some children no 
formal testing had been done. However, the research psychologists could make 
inferences based upon analyses of all available data, including reports pertaining to 
developmental data, recorded observations during assessments, test data reported and 
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from preschool visits and make a conclusion about the child’s general cognitive 
ability and then classify the child into an appropriate cognitive group: 
 
(a) Clear indication of or highly suspected learning disability/mental retardation 
according to DSM-IV (Learning disability/mental retardation group) 
 
(b) Indications of learning problems and developmental delay, but a definite 
classification into a specific cognitive level group was not possible (Developmental 
delay group). 
 
(c) Several indications of general cognitive ability within the normal range (Normal 
intelligence group). 
 
Speech and language assessment 
 
The speech and language pathologist in the research team performed a structured 
multi-item telephone interview or sent a questionnaire containing the same items to 
the parents [233]. 
 
Study II 
 
The study includes two parts: a) a register study and b) a parental interview. 
 
a) In the register study, the ASD group was contrasted with the general population 
regarding pre- and perinatal data, obtained from The Swedish Medical Birth Register 
(SMBR) and Statistical Central Bureau of Sweden (for information on paternal age 
and country of birth). To perform the study, an ethical approval and an approval from 
The Swedish Board of Health and Welfare were required. Consequently, all personal 
data were coded.   
 
The comparison group consisted of all children born 2002-2006 in Stockholm 
County, excluding children with diagnosis of ASD.  
 
The variables that could be analyzed using register data were: parental country of 
birth, parental age at child’s birth, maternal pre – and intrapregnancy medication and 
mode of delivery. For 21 children register data was not available in the SMBR. 
 
b) In the parental interviews the following information was investigated: the 
occurrence of first-degree relatives with ASDs and other neurodevelopmental 
problems (intellectual disability, ADHD, speech- and language problems and dyslexia 
– clinically diagnosed or qualifying for educational support) and/or a history of 
psychiatric disorder. First-degree relatives were classified as ‘‘broader phenotype’’ 
when there was a report of ‘‘mild autism’’ – (social aloofness/social phobia/extreme 
shyness that had not been registered as a clinical diagnosis of ASD). 
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Study III 
 
Medical work-up 
 
Comprehensive medical information on each child was collected from maternity and 
obstetric care units, the Child Health Care Centre (CHC) and all hospital and 
outpatient clinics attended by the child. In addition to data from records, parents were 
interviewed regarding the child’s pre- and perinatal history, early development, and 
any genetic, neurologic or other clinically significant medical condition, including 
epilepsy.  
 
Parents were interviewed regarding a history of regression in the child and this 
information was compared to available data in CHC and medical records. 
Consistency was required between parental information and the notes in the records 
from CHC. Regression was defined as loss of more than five spoken words used 
communicatively in children more than 15 months of age. In children younger than 
15 months, regression was determined when there was a clear indication of loss of 
social interest and contact. 
 
Participating families were recommended genetic testing using array-based 
Comparative Genomic Hybridization (array-CGH) and testing for Fragile X. 
Conventional chromosomal karyotyping had previously been performed in many of 
the children. In girls with a clinical suspicion of Rett syndrome analysis of mutation 
MECP2 was performed. 
 
Medical and genetic conditions were defined as: (1) a significant intrauterine harmful 
exposure, (2) substantial prematurity (gestational age less than 29 weeks), (3) an 
identified genetic disorder including significant genomic imbalances identified with 
array CGH, (4) abnormal brain MRI findings and (5) a clinical diagnosis of epilepsy. 
 
Intervention 
 
All 208 children received intervention based on principles of Applied Behaviour 
Analysis (ABA). The study design was naturalistic. There was no randomization to 
type of treatment. Parental preference was the most decisive factor. The presence of 
medical/genetic condition did not affect the choice of intervention type. 
 
One group received ‘‘intensive’’ and the remainder ‘‘non-intensive’’ targeted 
intervention. The different levels of interventions were defined as: Intensive 
intervention based on ABA, i.e., early intensive behavioral intervention (EIBI), given 
at the preschool and by the parents at home with assistance from the centre, with the 
intention to treat (a) 15 h or (b) 25–30 h per week or 30–40 h per week. Non-
intensive targeted intervention based on ABA, consisting of different targeted types 
of training (toilet training, speech and language training, training of compliance or 
other specific training that the child was deemed to need). 
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Outcome measure 
 
The primary outcome measure was change in Vineland Adaptive Behavior Scale 
(VABS-II) composite scores between Time 1 (prior to intervention) and Time 2 (after 
two years of intervention). Numbers of children in the outcome analyses reflect the 
number of individuals that could be assessed according to the studied variable and to 
the Vineland change score. Raters blind to the type of intervention given measured 
the outcome. 
 
Study IV 
 
Collection of clinical data 
 
All available information regarding the child’s neurodevelopmental profile (subtype 
of ASD diagnosis, cognitive level and medical data (presence of congenital 
anomaly/malformation, any medical/genetic condition including epilepsy) were 
collected. Interviews examined the occurrence of parental conditions (occurrence of 
ASD, other neurodevelopmental problems, intellectual disability, attention-
deficit/hyperactivity disorder (ADHD), speech and language problems and dyslexia – 
clinically diagnosed or qualifying for educational support) and/or a history of 
psychiatric disorder. Parents were classified as having “broader phenotype ASD” when 
there was a clear report of “mild autism” – (social aloofness/social phobia/extreme 
shyness that had not been registered as a clinical diagnosis of ASD). These data were 
all collected prior to the genetic testing. 
 
Genetic testing 
 
Conventional karyotyping had been performed in some children prior to the study start. 
Testing with chromosomal micro-array was performed with different array-CGH 
platforms (244 and180 K Agilent Technologies and 180 K Oxford Gene Technology). 
All had whole genome coverage. Analysis of microarray data was performed using 
DNA analytics (Agilent technologies) or Cytosure Interpret (Oxford Gene Technology) 
software. 
 
Where samples were available, parental testing was carried out to investigate mode of 
inheritance. Different methods were used (array-CGH, FISH, MLPA). 
 
Classification and interpretation of identified CNVs was based on available information 
in medical literature and different databases (DGV, Decipher) and done according to 
current guidelines [71] and recent reviews [90]. CNVs were classified in three 
categories: pathogenic, variants of unclear clinical significance (VOUS) and benign. 
Mode of inheritance (de novo or transmitted), type of CNV (deletion/duplication) and 
gene content were taking into consideration. CNVs previously known to be associated 
with a genomic disorder, de novo CNVs and large (> 500 Kb), rare CNVs and CNVs 
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that affected known candidate genes (e.g. NRXN1, CNTNAP2) were classified as 
pathogenic.  
 
Molecular analyses of MECP2 mutation was done when there was a clinical suspicion 
of Rett syndrome and testing for Fragile X was performed in a large proportion of the 
children when the chromosomal microarray was normal. 
 
 
5 STATISTICAL ANALYSES 
 
In all studies, comparisons between two groups (e.g. ASD vs. non-ASD) of the 
distribution of a dichotomous variable (e.g. gender) were performed. In some studies 
we focused on odds ratios with corresponding confidence intervals and in some studies 
we only reported p-values. In all cases when we reported a significant difference we 
confirmed that the difference was significant by using chi-square analysis using SPSS 
(version 19) exact test.  
 
Group means were compared using a) Students t-test, or b) ANOVA followed by pair-
wise post hoc analyses (Fischer’s LSD). For heavily skewed data and/or unequal group 
sizes, a Kruskal-Wallis test, followed by separate Mann-Whitney U-tests were used 
instead. 
 
An alpha level of .05 was used for all statistical analyses in all studies. 
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6 RESULTS 
 
Study I 
 
ASD diagnoses 
 
The referral diagnosis of the 208 children were; autistic disorder (n=133), PDD-NOS 
(atypical autism) (n=62), Asperger’s syndrome (n=6) and Childhood Disintegrative 
disorder (n=2) and in 5 cases an unspecified diagnosis of autism spectrum disorder 
had been given. 
 
Cognitive levels 
 
Of the 208 children, 80 belonged to the learning disability/mental retardation group, 
81 to the developmental delay group, and 47 belonged to the normal intelligence 
group.  
 
Table 1  
Cognitive groups  
 
 Normal intelligence Developmental delay Learning disability Total 
Boys 40 70 66 176 
Girls 7 11 14 32 
Total 47(23%) 81(39%) 80(38%) 208 
 
 
Adaptive behavior – Vineland Adaptive Behavior Scales (VABS-II) 
 
 
The three cognitive level groups were compared with respect to results on total score 
and on the four domains of the Vineland Adaptive scales II, Communication, Daily 
activities, Social and Motor function. Means (95% confidence intervals) and effect 
sizes are presented in Table 3.  
 
The results on the four domain scores of the VABS-II were related to cognitive 
levels. The developmental delay group and the learning disability/mental retardation 
group exhibited profiles with very low results on the Communication and 
Socialization scales and higher scores on Daily Living Skills and Motor Skills. The 
group with normal intelligence showed similar results albeit not as prominent. 
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Table 2  
Cognitive groups and Vineland Adaptive Behavior Scales-II 
 
Vineland domain Normal intelligence Developmental delay Learning disability Effect size (η2) 
Composite Score 78.89 (76.46-81.32) 70.37 (68.54-72.20) 61.18 (59.30-63.07) 0.40 
Communication 87.85 (84.58-91.12) 69.76 (67.28-72.26) 56.03 (53.46-58.60) 0.53 
Daily Living skills 84.00 (80.91-87.09) 76.74 (74.39-79.10) 66.00 (64.15-69.01) 0.29 
Socialization 74.85 (72.23-77.47) 69.78 (67.78-71.77) 63.57 (61.51-65.62) 0.19 
Motor skills 81.33 (78.07-84.58) 78.26 (75.80-80.72) 70.24 (67.70-72.77) 0.14 
 
Speech- and language level 
 
At the time of the first assessment 27 of the 208 children (13%) of the children had no 
words at all, 68 (33%) had a few single words, 48 (23%) had a few communicative 
sentences, and 65 (31%) had phrase speech with or without echolalia. 
 
Children (n=156) demonstrated a marked delay in the development of expressive 
vocabulary according to CDI/Mac Arthur. Statistical analysis comparing expressive 
vocabulary across the three cognitive subgroups confirmed that the variability in 
word production was significantly related to the cognitive level. 
 
Figure 3 
Expressive vocabulary in ASD cases and typically developing children 
 
 
The scatter plot displays the expressive vocabulary from CDI in number of words by the children’s age 
in months. The 50th percentile for typically developing children aged 16–28 months is indicated by the 
ascending solid line.  
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Independent walking and toe-walking 
 
Of the 208 children 138 (66%) started to walk unsupported before age 15 months, 48 
(23%) between 15 and 18 months, and 21 (10%) after 18 months of age. One child 
did not walk at first examination (age 40 months). Median age for walking was 13 
months.  Toe walking from the start of walking was present in 70 of the 208 children 
(34%), 39 of these (19%) had very clear and persistent toe walking.  
 
Activity level 
 
Hyperactivity was reported in a large proportion of the children, 87/208 (42%) 
unanimously by the parent and the examining physician. 98/208 (46%) had an activity 
level within the normal variation. Only seven children (3%) were classified as 
hypoactive. 
 
Co-existing epilepsy 
 
Twelve children (6%) had a history of epilepsy at the referral. Three of the twelve had 
their epilepsy onset classified as infantile spasms.  
 
Regression 
 
Regression was defined as loss of expressive language skills (loss of > 5 words used 
communicatively). In 46/208 (22%) a regressive trajectory was described and medical 
records from CHC supported this information. In 20 (10%) regression occurred after an 
apparently normal development and 26 children had a history of regression after a 
delayed early development.  
 
 
Study II 
 
Register data revealed that parents born outside Europe had a two-fold increased risk of 
having a child with ASD compared to parents born in Europe. 
 
Advanced paternal age (> 40 years) at the child’s birth was associated with an increased 
risk for ASD in the offspring (95 % CI= 1.0-2.1). No increased risk was found in 
association with advanced maternal age. 
 
The use of psychoactive medication during pregnancy was significantly higher in the 
ASD mother group compared to the register controls. Antidepressants (SSRI) were 
used in 4.3 % of ASD mothers vs. 1% in the controls (95 % CI=2.19-9.05). Similar 
differences were revealed with regard to the use of neuroleptics, sedatives and sleep-
inducing medication (95 % CI=2.5-8.0). 
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The frequency of caesarean section was significantly higher in mothers of children 
with ASD (27.8% vs. 19.8% (95%, CI = 1.12–2.13, p=0.009). The difference was 
accounted for by more scheduled sections (95% CI = 1.2–2.7, p=0.003). The 
frequency of breech presentation and other obstetric rationales were not increased in 
the ASD-group.  
 
The interviews showed significant gender differences as to types of neurodevelop-
mental/psychiatric disorders in first-degree relatives. Female first-degree relatives 
displayed higher rates of depression, including bipolar disorder, and other psychiatric 
disorders (anxiety disorder, recurrent psychosis, anorexia nervosa, and obsessive–
compulsive disorder) than male relatives, who had comparatively higher rates of 
ASDs, broader phenotype, dyslexia, speech- and language impairment and ADHD. 
 
Figure 4 
Gender distribution of conditions in first-degree relatives 
 
 
 
 
Study III 
 
A medical/genetic condition, including epilepsy, was identified in 38 of the 208 
children (18%). A single gene disorder was found in seven of the children (tuberous 
sclerosis complex (3), Fragile X (1), Rett syndrome (2) and Pyridoxine (B6) 
dependency (1). A clinical diagnosis of Pierre Robin syndrome was present in one 
child. In one child a deletion 22q11.2 was detected by conventional chromosomal 
analysis. In 11 of 162 children that could be analyzed with array-CGH a clinically 
ASD Broaderphenotype
Dyslexia/la
nguage ADHD
Intellectual
disability
Other
psychiatric
Depression
/bipolar
Male 18 17 10 10 0 1 5
Female 5 7 4 5 3 10 22
0
5
10
15
20
25
  
significant
(gestationa
pregnancy
foetal alco
congenital
present in 
(see fig 5) 
 
Figure 5 
Overview 
 
 
 
Any med
significant
with those
 
Of the 32
rate in boy
 
In childre
children w
(95 % CI =
 
A history
regression
as compar
0.008). In
(35/102) v
p=0.001). 
 
Epilepsy w
% CI = 0.
 aberration
l week 24
 and in one
hol spectrum
 hydroceph
a total of 18
ASD aetiol
ical/genetic
ly, found i
 who had A
 girls, 10 h
s was 28/1
n with the 
ith ASD a
 1.01–8.60
 of regress
 was more 
ed with chi
 children w
s. (11/106
as not mor
19–2.47, n.s
 was iden
 and 28). O
 adopted ch
 disorder. 
alus. Of th
 children. I
ogies in 208
 condition
n children 
SD withou
ad an iden
76 (95 % C
combinatio
nd borderli
; p = 0.047
ion was d
common in
ldren with 
ith the com
) in childr
e prevalent
.). 
37
tified. Tw
ne child h
ild a there 
Three had a
ese 27 chi
n ten of the
 children 
 includin
with the co
t ID (CI 95
tified med
I = 1.03–5.
n of ASD 
ne or avera
). 
escribed in
 children w
atypical au
bination o
en with A
 in children
 
o children
ad been ex
was clinica
bnormal M
ldren 7 als
se no specif
g epilepsy
mbination 
% = 0.98–4
ical/genetic
62, p = 0.04
and ID, 13
ge cognitiv
 46/208 c
ith a clinic
tism/PDD-N
f ASD and 
SD withou
 with regre
P
E
G
C
E
P
C
N
 had been
posed to v
l presentati
RI findings
o had epil
ic aetiology
 was mo
of ASD an
.17, p = 0.0
 condition.
3). 
/102 had e
e function,
hildren (22
al diagnosis
OS (95% 
ID, regress
t ID (95 %
ssion than i
renatal exposur
xtreme prematu
enetic syndrom
NS malformatio
pilepsy without 
athogenic Copy
opy Number Va
o condition iden
 born pre
alproic aci
on consiste
 and one ch
epsy. Epile
 had been i
re often, 
d ID, as c
57). 
 The corre
pilepsy, wh
 5/106 had 
 %). A h
 of autistic
CI = 1.37–
ion was rep
 CI = 2.
n those wit
e
rity
e with ASD
n
etiology
 Number Varia
riant Unclear S
tified
maturely 
d during 
nt with a 
ild had a 
psy was 
dentified 
 
but not 
ompared 
sponding 
ereas in 
epilepsy 
istory of 
 disorder 
8.14, p = 
orted in 
14–9.51, 
hout (95 
nt
ignificance
 38 
 
Outcome in relation to medical/genetic conditions, including epilepsy 
 
Children without medical/genetic condition had a positive VABS-II change score at 
Time 2 (compared to Time 1) whereas children with a medical/genetic condition 
(including epilepsy) had a negative VABS-II change score. The difference was not 
significant. Type of intervention, intensive vs. non-intensive, did not significantly 
affect outcome in any of the four groups. 
 
Figure 6 Mean VABS Composite Score at Time 1 and Time 2 in children with (n=34) 
and without (n=158) any medical/genetic condition including epilepsy.  
 
 
Children without epilepsy had a positive VABS-II change score at Time 2 (compared 
to Time 1) whereas children with epilepsy had a negative VABS-II change score. The 
difference was significant. 
 
Figure 7 Mean VABS Composite Score at Time 1 and Time 2 in children with (n = 15) 
and without (n = 177) epilepsy. 
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Children without a history of regression had a positive VABS-II change score at Time 
2 (compared to Time 1) whereas children with a regression had a negative VABS-II 
change score. The difference was significant. 
 
Figure 8  
Mean VABS Composite Score at Time 1 and Time 2 in children with (n=40) and 
without (n=150) regression. 
 
 
Children who had been referred after the age of three years had increased their 
VABS-II score at Time 2 (compared to Time 1) whereas children who had been 
referred before the age of three had decreased their VABS-II score. The difference 
was significant. 
 
Figure 9  
Mean VABS Composite Score at Time 1 and Time 2 in children who had been referred 
before (n=65) or after (n=127) age three years. 
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Study IV  
 
Genetic testing 
 
Genetic testing with array-CGH was performed 136 boys and 26 girls. Seven children 
had a previously identified genetic disorders and two were not assigned to testing since 
their ASD affected siblings had normal chromosomal microarray. Testing for Fragile X 
was performed in 142 of the children and a mutation was found in one boy. 
Conventional karyotyping had been performed in 80 children. Targeted analysis with 
FISH, revealed a deletion in chromosome region 22q11.2in one girl. This case has been 
included as a pathogenic CNV in the following analyses since it would have been 
detected by array-CGH. Of the 26 girls, three were clinically suspected of having Rett 
syndrome and two of these were found to carry a MECP2 mutation. 
 
Array-CGH results 
 
A pathogenic CNV was identified in 13/162 (8%) children and an additional de novo 
deletion 22q11.2 was previously identified. In another 14 children, CNVs classified as 
VOUS were found – thus, in 28 of the 162 of the children (17%) a putative risk 
conferring genomic imbalance was identified. In 24/28 children the inheritance status 
could be determined. Seven of the 24 children had a de novo chromosomal aberration 
(4.3 % of the total ASD sample).  Ten of the CNVs were paternally inherited and nine 
CNVs maternally inherited. In one case, both parents transmitted a heterozygous 
deletion in the same gene. Two families declined parental testing and two children were 
adopted. 
 
In some cases more than one CNV or other chromosomal rearrangements were 
identified. In the group of children with pathogenic CNVs, one boy had a paternally 
transmitted duplication in region 16p11.2 and an additional mosaic trisomy 
chromosome 9. One girl had a de novo deletion in region 22q13.3, affecting the 
SHANK3 gene. In addition two more CNVs were found - a maternally transmitted 
duplication in region 9p24.2 and a paternally transmitted deletion in region 9q33.1. In 
the group of children with CNVs classified as VOUS one boy had two deletions – one 
detected in region 4q22.1 and the second in region 13q21.2, both paternally inherited. 
One boy had two paternally transmitted duplications, one in region 18p11.23 and a 
second in region 18p11.22. One boy had a paternally inherited duplication in region 
7q36.1 and a maternally inherited duplication in region 11p15.1. 
 
Six of 26 girls (23%) were found to have a CNV. Of these, four were classified as 
pathogenic and two as VOUS. Three girls had a de novo CNV, one was paternally, one 
maternally inherited and in one case both maternally and paternally transmitted. 
Twenty-two boys of 136 (16%) were found to have a CNV. Ten boys had a pathogenic 
CNV (7%) and 12 boys had VOUS. Five boys had a de novo CNV, in eight the CNVs 
were paternally inherited and in seven boys it was maternally inherited.  
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A pathogenic CNV was more often identified in girls although the difference was not 
statistically significant (OR=2.29, 95% CI = 0.66-7.96). 
 
No association was found between paternal or maternal age and the rate of de novo 
CNVs. 
 
A pathogenic CNV was identified in 9% of children with autistic disorder and in 6% of 
children with PDD-NOS. Including CNVs characterized as VOUS, any CNV was 
found in one in five children with autistic disorder vs. one in ten in children with 
atypical autism. No pathogenic CNV was found in the nine children with Asperger’s 
syndrome. However, two cases with Asperger´s syndrome had CNVs characterized as 
VOUS. Furthermore, a pathogenic CNV or a VOUS was found in 3/14 children who 
did not meet full criteria for ASD but had autistic traits in combination with other 
neurodevelopmental disorders.  
 
Figure 10 
Pathogenic CNVs 
 
Sex Phenotype Cytogenetic location Gain/Loss Size Inheritance Gene identifiers 
m AD/ID/Non-syndromic 2p16.3 loss 110kb maternal NRXN1 
f AD/ID/Non-syndromic 2p16.3 
2p16.3 
loss  
loss 
419kb 
169kb 
maternal 
paternal 
NRXN1 
NRXN1  
m AA/N-low/ Syndromic 2q21.1 loss 434kb maternal ARHGEF4,GPR148 
m Aut traits/ID/Non-syndromic 7q35 loss 151kb paternal CNTNAP2 
m AA/N/ Syndromic 16p11.2 loss 545kb de novo KCTD13 
m AD/N-low/Non-syndromic 16p11.2 loss 523kb paternal KCTD13 
m AD/ID/ Syndromic 16p11.2 loss 220kb de novo SH2B1 
m AA/N-low/Non-syndromic 16p11.2  
chr9 
gain 
trisomy(mos) 
547kb 
NA 
paternal 
NA 
KCTD13 
NA 
m AD/ID/Syndromic 17p11.2 gain 3,47Mb de novo RAI1 
m AD/ID/ Syndromic 17p13.3 gain 1.02Mb de novo YWHAE, CRK 
m AA/ID/Non-syndromic 20p13.3 gain 549kb de novo SCRT2 
f Aut traits/syndromic 22q11.21 loss  de novo  
f AD/ID/ Syndromic 22q13.31q13.33 loss 3,04Mb unknown SHANK3 
f AD/ID/Syndromic 22q13.33 
9p24.2 
9q33.1 
loss 
gain 
loss 
25kb 
420kb 
22kb 
de novo 
maternal 
paternal 
SHANK3 
GLIS3 
ASTN2 
 
NA=Non-applicable, m=male, f =female, AD=Autistic Disorder, AA=Atypical Autism, Asp=Asperger,  
Aut traits= autistic traits, ID=intellectual disability IQ<70, N-low=border-line IQ 70-80 
N=IQ>70.1Deletion detected by karyotyping, array-CGH not done  
 
Pathogenic CNVs were more often identified in children with ASD and co-occurring 
ID or borderline intellectual functioning – 10.7% compared to 2.4% in children with 
ASD and normal cognitive level (OR=2.15, 95% CI=0.46-10.0 n.s). Including CNVs 
categorized as VOUS, any CNV was more often found in the ASD+ID group compared 
to ASD without ID (OR=2.4, 95% CI=1.00-5.64, p=. 061). 
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Among children with a pathogenic CNVs or a VOUS (n=28), ten had a congenital 
malformation or major dysmorphology vs. twelve of 134 in children with no CNV 
detected. A significantly increased rate of CNVs was found in children with congenital 
malformations or dysmorphology compared to those without (OR=5.65, 95% CI=2.1-
15.0, p < .001). 
 
CNVs were not more prevalent in children with ASD and co-occurring epilepsy.  
 
A non-significant trend indicated that in children with a history of autistic regression 
pathogenic CNVs and VOUS were more often identified compared to children with no 
history of autistic regression (OR = 2.12; 95% CI= 0.82-5.48,n.s.). 
 
Figure 11 
Copy Number variants of unclear significance 
 
Sex Phenotype Cytogenetic location Gain/Loss Size Inheritance Gene identifiers 
m AD/ID/Syndromic 4q22.2 
13q21.2 
loss 
loss 
75kb 
60kb 
paternal 
paternal 
GRID 
DIAPH3 
m AD/ID/Non-syndromic 5p15.1p14.3 gain 1.46Mb unknown BASP1 
m AD/N-low/Non-syndromic 5p15 gain 769kb maternal FBXL7 
m AD/ID/Non-syndromic 8p23.1 gain 184kb paternal MCPH1 
f AA/N/Non-Syndromic 9q22.1 gain 845kb paternal CENPP,ECM2,IPPK,BICD 
m Asp/N-low/Non-syndromic 9q34.3 gain 89kb maternal GRIN1,MAN1B1 
m AD/ID/Non-syndromic 10q23.1 loss 62kb maternal NRG3 
m Aut traits/N/Non-syndromic 14q23.3 loss 75kb unknown GPHN 
m AD/ID/Non-syndromic 15q13.1 
15q13.1 
gain 
gain 
301kb 
270kb 
paternal 
paternal 
OCA2 
APBA2 
m AD/ID/Non-syndromic 16p12.3 gain 332kb paternal ITPRIPL2, SYT17, TCM5 
f Asp/N/Non-Syndromic 18p11.21 loss 297kb maternal IMPA2 
m AD/ID/Non-syndromic 18p11.23 
18p11.22 
gain 
gain 
433kb 
116kb 
paternal 
paternal 
PIPRM 
ANKRD12 
m AD/ID/Non-syndromic 7q36.1 
11p15.1 
gain 
gain 
310kb 
186kb 
paternal 
maternal 
XRCC2, ACTR3B 
NELL1,SLC6A5 
m AA/N-low/Syndromic Xp11.4 gain 144kb maternal3 TSPAN7 
 
NA=Non-applicable, m=male, f =female, AD=Autistic Disorder, AA=Atypical Autism, Asp=Asperger,  
Aut traits= autistic traits, ID=intellectual disability IQ<70, N-low=border-line IQ 70-80 N=IQ>70  
 
 
Array-CGH results and neurodevelopmental/psychiatric conditions in 
parents 
 
Of the 28 identified CNVs, eight were de novo and 18 were inherited. In two cases 
parental samples were not obtainable. A parental history of any neurodevelopmental 
condition, psychiatric disorder or being classified as being within the broader 
phenotype autism spectrum was reported in 59 of the 320 parents (18%). The frequency 
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of these conditions was compared between those parents who transmitted a CNV to 
those who did not transmit any CNV.  
 
Nine of the children had a maternally transmitted CNV. Maternal depression, prior to 
the birth of the child was more often reported in mothers who transmitted a CNV 
(classified as pathogenic or VOUS) compared to those mothers where no CNVs were 
identified in the offspring (OR= 3.22, 95% CI= 0.74-14.0 n.s.). Two mothers 
transmitted deletions affecting the NRXN1 gene. One mother diagnosed with ADHD 
and mild epilepsy transmitted a deletion in 2q21.1. Moreover, one mother, transmitted 
a deletion in 18p11.21 had symptoms within the broader phenotype autism spectrum. 
Any neurodevelopmental or psychiatric condition was significantly more often reported 
in mothers who transmitted a pathogenic CNV/VOUS (5/9) compared to those mothers 
where no such CNV was identified in the offspring (OR=4.7, 95% CI=1.2-18.8, p =. 
031).  
 
The study could not demonstrate any association between paternal transmission of 
CNVs and paternal neurodevelopmental or psychiatric conditions (OR=1.4, 95 % CI = 
0.28-7.08 n.s.). 
 
When combining mothers and fathers who transmitted CNVs, an increased frequency 
of neurodevelopmental and psychiatric conditions was found in parents who 
transmitted a CNV to the offspring. Any parental condition was found in 7/19 CNV 
transmitting parents compared to 48/268 in cases where no transmitted CNV was 
identified. According to using Fisher´s exact test the difference was however not 
significant (OR= 2.67, 95% CI= 1.0-7.1, p= .061). 
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7 DISCUSSION 
 
General findings 
 
The study group of preschool children with ASD that had been referred for early 
intervention differed considerably with regard to severity of the core symptoms of ASD 
and exhibited a wide variety of co-existing disorders and conditions. Approximately 
50% of the children had a general cognitive level within the intellectual disability 
spectrum. In a substantial subgroup genetic and other medical conditions were found. 
The epilepsy prevalence was significantly higher than in the general child population. 
 
The results regarding pre- and perinatal ASD risk factor characteristics were consistent 
with previous and more recent epidemiological studies; e.g. advanced paternal age, 
parents born outside Europe, maternal psychoactive medication and scheduled 
caesarean section were all associated with increased ASD risk in the off-spring. 
 
Psychiatric and neurodevelopmental conditions in 1st degree relatives differed 
according to gender. Male 1st degree relatives often had ASD or broader phenotype 
symptoms, speech-and language impairments and ADHD. Female 1st degree relatives 
more often had a history of depression, bipolar disorder or other psychiatric disorders. 
 
The presence of an identified medical/genetic condition, including epilepsy resulted in 
a poorer adaptive outcome at the 2-year follow up. Children with such conditions had 
been referred at an earlier age. A poorer outcome was also found in children with a 
history of regression. 
 
The genetic work-up including array-CGH yielded a significant increase of identifiable 
causes. Children with ASD and ID/congenital malformation more often had a causative 
CNV.  
 
The overall findings implicate that comprehensive and collaborative neuro-
developmental, cognitive and medical work-up is warranted in children with ASD.  
 
Limitations and strengths 
 
The children in this population based study group had been diagnosed at Child and 
Adolescence Mental Health Services and at Neuropaediatric units in Stockholm 
County. Diagnostic assessment policies varied between referring units. Children were 
young, the youngest around two years of age, weakening the diagnostic precision. In 
this group many children had severe cognitive and behavioural symptoms prompting an 
early identification. A small group, not included in the study, had been referred to their 
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local habilitation centre, due to ASD in combination with more complex medical 
conditions and needs.  
 
Thus, our study group was population-based and considered to be representative of 
preschool children with early-diagnosed ASD, except for the most severely impaired 
children. The high proportion of children with ID can probably be attributed to that 
most children with high functioning autism/Asperger syndrome will be diagnosed later 
in life.  
 
Our sample size is small, which affects the power of the statistical analysis and the 
results indicating significant findings must be interpreted with caution. Furthermore, 
associations not detected might have been present with a larger sample size. 
 
Strengths of the study, was the very low attrition rate, (> 95% participated in the two-
year follow-up assessment) and that the developmental profiles included evaluation at 
two time points. Comprehensive clinical and medical data could be obtained for each 
child and genetic analyses were performed in a large group. Outcome was measured by 
observers blind to the type of intervention given. 
 
8 Discussion of results in each of the four studies 
 
Study I 
 
Highly heterogeneous clinical profiles were found in the study group. Major subgroups 
at referral 65%, had been diagnosed with autistic disorder, PDD-NOS had been found 
in 30% and in 3% Asperger syndrome. In addition, 2% had been diagnosed with 
unspecified ASD. Intellectual disability and borderline intellectual functioning was 
found in approximately 75% and correlated to adaptive behaviour (VABS-II). In some 
children the autistic symptoms were presenting and dominating, whereas in other 
children a general cognitive delay was more prominent than the autistic features. In this 
group, many children also had a delayed gross motor function, some had epilepsy and 
some exhibited dysmorphology. The highly variable speech- and language function 
also add to the vast heterogeneity in the study group. One subgroup (42%) exhibited 
significant hyperactivity. The conclusion of the study was that preschool children 
diagnosed or with suspected ASD require comprehensive and broad clinical 
assessments, including a medical evaluation. Children diagnosed with ASD at early age 
also need cognitive and medical re-evaluation.  
 
 Study II 
 
Pre- and perinatal risk factors; e.g. paternal age, parents born outside Europe, maternal 
use of SSRI, other psycho-active medication during pregnancy and scheduled caesarean 
section were all found to confer a significant increased risk for ASD in the offspring.  
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Advanced parental age has been associated with ASD in several studies. High paternal 
age is also a risk factor for ID and schizophrenia. De novo mutations in 
spermatogenesis increase with age and it has been shown that ASD risk conferring 
sequence mutations more often have a paternal origin. We were not able to detect 
maternal age as a risk factor, probably due to the limited size of our study. 
 
The risk associated with ASD in children with parents born outside Europe has been 
confined to ASD combined with ID. Parental migrational status has also been shown to 
be a risk factor in severe ID [234]. Several mechanisms have been studied and 
discussed; consanguinity, vitamin D deficiency, maternal stress and exposure to a 
different panorama of viral infections during pregnancy.  
 
The increased risk for ASD associated with maternal use of SSRI was confined to ASD 
without ID in a recent Swedish study [160].  
 
The increased rate of scheduled caesarean section has likewise been shown in other 
studies. However, no conclusions with regard to underlying factors have been drawn. 
Our interpretation, based on maternity records, of the observed difference is that 
scheduled caesarean sections were more common among mothers of ASD children, due 
to emotional vulnerability and fears of natural delivery. 
 
Psychiatric and neurodevelopmental conditions in 1st degree relatives differed 
according to gender; male 1st degree relatives often had ASD or broader phenotype 
symptoms, speech-and language impairments and ADHD. Female 1st degree relatives 
more often had a history of depression, bipolar disorder or other psychiatric disorders. 
ASD susceptibility genes are probably not specific to ASD but to a wider spectrum of 
neuropsychiatric developmental disorders. This could well reflect that shared genetic 
susceptibility factors present in gender specific patterns. 
 
Study III 
 
All 208 children had received intensive or non-intensive/targeted early intervention 
based on Applied Behavioural Analysis (ABA) principles. The study was naturalistic 
and there was no randomization to treatment type. Parental preference was the most 
decisive factor and the presence of a medical/genetic condition did not affect choice of 
intervention type.  
 
A relatively large proportion (18%) of the preschool children with ASD had an 
identifiable medical/genetic disorder including epilepsy - reaching 24 % in the group of 
children with ASD and ID. About one in five had a history of autistic regression and 
about one third had been referred before three years of age. All these factors were 
associated with a more negative outcome measured as change in VABS-II score during 
the 2-year follow-up. Children identified at a low age will have an increased risk of 
having co-occurring intellectual disability and genetic and medical co-existing 
disorders, reflecting an apparent and more severe underlying brain dysfunction 
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compared to children diagnosed at higher ages. The results underscore the importance 
of considering medical/genetic aspects in young children with ASD and the 
requirement to individualize and tailor intervention according to their specific needs. 
 
Study IV 
 
The overall result of the study was coherent with previous studies using chromosomal 
microarray in children with ASD. A clinically significant CNV could be identified in 
8.6 % of children with early-diagnosed ASD. De novo CNVs were identified in 4.3 % 
and inherited CNVs in 4.3%. It is unlikely that CNVs classified as pathogenic are the 
single ASD genetic risk factor in an affected individual – rather a detected genomic 
imbalance is acting in concert with multiple modifiers with lower effect size resulting 
in a distinctive phenotype. 
 
Albeit the robust evidence for genetic factors in ASDs, a specific genetic cause can be 
detected in about 25 % of individuals with ASD with current available technologies. In 
individuals with ASD, Copy Number Variants, conferring ASD susceptibility are found 
in 5-15%, mostly identified as de novo CNVs in sporadic cases. These CNVs are often 
rare, highly penetrant and the parental origin of de novo CNV events points to a trend 
with excess of maternal origin [32, 89]. Furthermore recurrent and inherited CNVs 
contribute to ASD susceptibility. Recurrent CNVs include those found in established 
microdeletion and microduplication syndromes, such as deletions and duplications on 
chromosome region 16p11.2, duplications 15q11.2, deletions and duplications 15q13.2, 
duplications 17q11.23 and deletion on chromosome region 22q11.2.  
 
In this study, CNVs were 2-fold more often identified in children with autism spectrum 
disorder and co-existing intellectual disability and significantly more often in children 
with ASD and congenital malformations or dysmorphology. Several studies have 
reported high proportion (10-20%) of pathogenic CNVs in individuals with intellectual 
disability without ASD [94, 135] and in this study a large proportion of the children had 
co-existing ID. Some authors emphasize the genetic overlap between ASD and ID 
[184] while others report that the detection of a de novo CNV is not a useful predictor 
of low IQ in ASD [32]. It has been shown that lower IQ in individuals with ASD is 
associated with the number of genes affected by CNVs [32, 235]. The presence of 
dysmorphology/congenital anomalies increases the chances of detecting a de novo copy 
number variant in individuals with ASD [99].  
 
Also in children with significant neurodevelopmental impairments in combination with 
autistic traits, but not meeting ASD criteria, a pathogenic CNV was present in as many 
as 14%. Pathogenic CNVs were slightly more often found in girls. Previous studies 
have documented that a higher proportion of females with ASD carry detectable de 
novo copy-number events than do males and that the events are larger [31] and that a 
trend toward more gene-rich CNVs has been observed in females [32]. 
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Eight of the 162 children in the study were found to have a well-established 
microdeletion or microduplication syndrome. CNVs involving 16p11.2 (deletions and 
duplications) were found in 2.4 % of the children. This region has repeatedly been 
reported in a substantial fraction (∼0.8%) of individuals with ASD [31, 32, 236]. 
Deletions and duplications in this region have been associated with ID, non-ASD 
psychiatric disorders and have also been detected in unaffected individuals.  
 
A double-hit model where CNVs or other chromosomal structural rearrangements 
combine and cause the ASD phenotype has been described in previous studies [70, 90]. 
In this study two cases had a pathogenic CNV and a minor second CNV. Three cases 
had CNVs classified as VOUS and additional minor aberrations. 
 
There are a several specific genes, where mutations have repeatedly been found to be 
risk factors in ASD, such as NLGN3 [66], NLGN4 [66, 237], SHANK2 [91, 238] , 
SHANK3 [54, 239], NRXN1  [59, 60, 92], NRXN3 [240], SHANK 1 [37], ASTN2 [96, 
241], CNTN4 [242] and CNTNAP2 [243] [52]. In this study, seven cases had a CNV 
encompassing one of these genes (NRXN1, SHANK3, ASTN2 or CNTNAP2).  
 
Advanced paternal age has been shown to be a risk factor for ASD and ID [129, 135, 
136]. In a study of cases with ID (without ASD) by Hehir-Kwa et al, rare de novo 
CNVs was associated with a paternal origin and with higher paternal age[135]. In this 
study we could not document that parental age affected the rate of de novo CNVs in the 
offspring. 
 
There was a trend indicating higher rates of maternal psychiatric or neuro-
developmental conditions prior to the child´s birth in mothers who transmitted CNVs 
(classified as pathogenic or VOUS) compared with mothers who did not transmit such 
CNVs. In fathers transmitting such CNVs, no such trend could be documented. 
 
Recent guidelines suggest the use of chromosomal micro-array for children with ASD 
or ID. Chromosomal micro-array increases the chance of giving an aetiological 
explanation to the parents and to provide better data when discussing recurrence risk 
for future siblings. 
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9 CONCLUDING REMARKS   
 
Autism spectrum disorders are not uncommon and have a major impact on the affected 
individual, the family and on the requirements for educational and societal support. Our 
study has demonstrated that preschool children with ASD differ significantly in 
cognitive and language abilities and in many other developmental aspects 
(hyperactivity, epilepsy). Prenatal risk factors play a role in ASD aetiology, although 
these risk factors are non-specific and the relative risk increase is mostly modest. 
Nearly one fifth of the children in our study had a medical or genetic condition 
identified. An important observation is that the presence of such a condition may 
influence the outcome of early intervention. The compartmentalization of services for 
young children with neurodevelopmental disorders may result in suboptimal 
recognition and treatment of co-existing medical and neuropsychiatric conditions. 
Thus, preschool children with ASD should have access to comprehensive 
neurodevelopmental, medical and genetic assessment, according to the “ESSENCE” 
concept (Early Symptomatic Syndromes Eliciting Neurodevelopmental Clinical 
Examinations) [244].  
 
Our study could identify pathogenic Copy Number Variants in a subset of children with 
ASD. Interestingly, the CNVs observed were in many cases affecting genes involved in 
synaptic development and function. Another group of CNVs occurred in regions in 
recently defined microdeletion or microduplication ASD-associated syndromes. Recent 
guidelines suggest the use of chromosomal micro-array for children with ASD or ID, 
the rationale for this being the superior diagnostic yield compared to conventional 
karyotyping. Chromosomal micro-array increases the chance of giving an aetiological 
explanation to the parents and to provide better data when discussing recurrence risk 
for future siblings. Hopefully, better understanding of specific phenotypic 
characteristics in cases with a defined aetiology will improve the medical and 
educational support.   
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10 FUTURE DIRECTIONS 
 
Rapidly evolving genomic technologies, such as whole genome sequencing, combined 
with increasingly large study cohorts will establish the extreme aetiological 
heterogeneity in ASD and other complex disorders and display the highly pleiotropic 
effects of ASD associated mutations [104]. An increasing number of ASD conferring 
specific genes will be identified and the role of common genetic polymorphisms will be 
clarified.  There is increasing evidence that in addition to protein-coding genes 
microRNAs may be involved in ASD aetiology [245]. The hypothesis that a large 
number of ASD risk gene variants affect proteins in specific functional networks will 
be better understood. It has been suggested that neurodevelopmental and psychiatric 
disorders are pathway disorders, i.e., that genes involved in ASD seem to converge on 
common pathways altering synaptic homeostasis. Recently it has been proposed that    
“synaptic clinical trials” should be designed and carried out to investigate the 
possibility of reversing phenotypes [246]. It is likely that the aetiological and clinical 
overlaps between childhood developmental disorders and adult psychiatric disorders 
will be better elucidated. The future diagnostic procedures will increasingly include not 
only more specific phenotypic symptom criteria but also far more genotypic data. 
Identifying specific functional networks involved in ASD and other complex disorders 
will speed up the development of targeted medications.  
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11 SVENSK SAMMANFATTNING 
 
Under de senaste 10 åren har det skett en mycket snabb utveckling av genetiska 
analysmetoder och möjlighet till databearbetning av extremt stora 
informationsmängder. Det mänskliga genomet har kartlagts i detalj. Många höggradigt 
komplexa interagerande mekanismer är involverade i regleringen av våra gener, liksom 
mellan gener och faktorer i miljön.  
 
Vi har fått nya metoder för att kartlägga orsaksfaktorer till utvecklingsneurologiska och 
psykiatriska tillstånd. Överlappande identiska genetiska förändringar återfinns hos barn 
med utvecklingsstörning, autismspektrumtillstånd (AST), ADHD och hos vuxna 
individer med psykiatriska diagnoser och pekar mot att gränserna mellan dessa tillstånd 
förefaller vara oskarpa. Begreppet ESSENCE( Early Symptomatic Syndromes Eliciting 
Neurodevelopmental Clinical Examination), som lanserades av Gillberg 2010 beskriver 
hur tidigt debuterande utvecklingsneurologiska symtom och funktionsnedsättningar i 
mycket hög utsträckning samexisterar och överlappar.  
 
Vid både utvecklingsstörning och autismspektrumtillstånd har man idag identifierat 
många hundra underliggande genetiska förändringar. Många av de gener som kopplas 
till dessa tillstånd är involverade i hjärnans utveckling. Särskilt verkar gener som styr 
synapsens mognad och funktioner ha en central roll. 
 
Autismspektrumtillstånd definieras i s.k. diagnosmanualer (DSM-IV, DSM-5 och ICD- 
10). De grundläggande svårigheterna hos individer med AST innefattar svårigheter med 
socialt samspel, med verbal och icke-verbal kommunikation samt förekomst av 
begränsningar i beteenden, rutiner och intressen. AST definierat i DSM IV innefattar 
autistiskt syndrom, atypisk autism (något lindrigare form) samt Aspergers syndrom, 
som kännetecknas av svårigheter med socialt samspel, förmåga till kommunikation och 
med begåvning inom normalvariationen men med begränsningar i intressen/beteenden. 
I den aktuella DSM-5 finns en övergripande diagnosterm; autismspektrumtillstånd. Hos 
barn och vuxna med AST förekommer i hög frekvens andra samtidiga svårigheter. En 
stor andel har varierande grad av utvecklingsstörning eller kognitiv förmåga i nedre 
normalområdet. Många individer med AST uppfyller även kriterier för samtidig ADHD 
med eller utan överaktivitet/impulsivitet. Epilepsi är inte ovanligt och hos unga vuxna 
med autism har närmare en tredjedel epilepsi.  
 
Kunskapen om autismspektrumtillstånd har ökat och det har under de senaste trettio 
åren skett en kraftig ökning av antalet individer som får en diagnos inom 
autismspektrat. Ett sådant tillstånd diagnosticeras numer hos ∼1% av befolkningen. Fler 
pojkar än flickor får AST diagnos; relationen anges ofta till 3-4:1, ännu mer förskjuten 
hos personer med AST och normal begåvning.  
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Epidemiologiska studier bl.a. av enäggs- och tvåäggstvillingar med AST, studier av 
syskon till barn med AST samt förekomsten av mildare symtom på autism hos 
släktingar – pekar på att genetiska faktorer spelar en avgörande, central och 
dominerande roll.  
 
Studier har också identifierat ett flertal riskfaktorer som är relaterade till miljön – i 
huvudsak under graviditeten då fostrets hjärna utvecklas men även vissa 
bakgrundsfaktorer hos föräldrarna har kopplats till ökad risk för AST. 
 
Vår forskningsgrupp har undersökt barn som fått diagnos AST före 4.5 års ålder och 
som remitterats till ett specialinriktat habiliteringscenter: Autism Center för Små barn i 
Stockholm. Barnen har diagnostiserats vid Barn- och ungdomspsykiatrisk mottagning 
(BUP) eller på någon av länets tre Universitetssjukhus med enheter för Neuropediatrik. 
Vi startade våra studier 2006 med syftet att följa upp och utvärdera effekter av tidig 
intervention. Totalt 208 barn var med i studien, 176 pojkar och 32 flickor. 
 
Vår första studie är en kartläggning av 208 barn som remitterats i åldrar 20-54 månader 
med avseende på typ av AST, förekomst av samtidig utvecklingsstörning, tal – och 
språknivå och medicinska tillstånd. Kartläggningen utgjorde en bas inför den planerade 
2-års uppföljningen. En stor andel av de tidigt remitterade barnen hade utöver AST 
också en samtidig utvecklingsstörning eller tecken på försenad generell kognitiv 
utveckling. Många uppvisade hyperaktivitet. Epilepsi fanns hos 6 %. Ungefär en 
femtedel av barnen hade haft en tillbakagång i sin utveckling, ofta omkring 18 
månaders ålder. 
 
I den andra studien jämfördes barnen med AST med en stor jämförelsegrupp med hjälp 
av Medicinska Födelseregistret med avseende på några riskfaktorer. Vi fann att barn 
med AST oftare hade en äldre fader och föräldrar födda utanför Europa. Mödrar till 
barnen med AST hade en signifikant högre användning av antidepressiva läkemedel, 
liksom annan psykofarmaka under graviditeten. Planerade kejsarsnitt var vanligare i 
gruppen med AST. I samband med föräldraintervjuer efterfrågades förekomst av 
utvecklingsneurologiska och psykiatriska tillstånd hos nära släktingar. Fäder och bröder 
hade en hög förekomst av AST eller hade mildare autismsymtom (broader phenotype). 
Mödrar och systrar hade en hög förekomst av depression och andra psykiatriska 
tillstånd. 
 
I den tredje studien redovisas medicinska och preliminära resultat från genetisk 
undersökning med s.k. array-CGH. Ett medicinskt eller genetiskt tillstånd förelåg hos 
18 % av de 208 barnen. Andelen barn med epilepsi när barnen är < 6.5 år är 9 %. 
Som mått på hur barnets adaptiva förmågor utvecklats, jämfördes skillnader i poäng på 
Vineland Adaptive Behavior Scales (åldersrelaterat instrument som mäter barnets 
fungerande i det dagliga livet). En mätning gjordes före start av tidig intervention och 
en ny efter två år. Resultaten visade att barn som remitterats före 3 års ålder/eller hade 
ett identifierat medicinskt eller genetiskt tillstånd inklusive epilepsi hade en sämre 
adaptiv utveckling. 
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I den fjärde studien redovisades resultaten där vi använt s.k. array-CGH för att 
genetiskt undersöka 162 barn. Vid utredning av barn med AST, har man tidigare ofta 
rekommenderat traditionell kromosomanalys och analys av Fragile X. Med dessa 
metoder påvisas orsak till AST hos drygt några procent av de undersökta. Den nya 
metoden - array-CGH - har ca 100 gånger bättre ”upplösningsförmåga” än den 
traditionella kromosomanalysen. 
 
Normalt har en individ en DNA uppsättning från modern och en från fadern, vilket 
innebär att alla sekvenser finns i två upplagor. Med array-CGH, kan man se om ett 
segment saknas (deletion) eller om ett segment förekommer i fler än två kopior 
(duplikation). Sådana variationer i antalet kopior (eng. Copy Number Variants = 
CNVs) förekommer hos friska och utgör en del av variationen mellan olika individer. 
Dock kan i synnerhet stora förändringar, där det saknas DNA segment kopplas till risk 
för sjukdom. Med hjälp av array-CGH kan man hos individer med AST identifiera 
olika ovanliga CNVs hos 5-15%, jämfört med hos friska kontroller (1 %). En CNV kan 
vara nedärvd från en förälder eller uppkommit de novo, i bildningen av spermier/ägg 
och då återfinnas i barnet men inte hos någon av föräldrarna.   
 
Av de 162 undersökta barnen hade 8.6 % en påvisbar CNV, som med största 
sannolikhet har relevans för barnets tillstånd. Hos ytterligare 8.6 % påvisades en CNV 
där det finns en osäker relevans. Hos barn med AST i kombination med 
utvecklingsstörning påvisades i något högre andel en CNV, liksom hos barn med AST i 
kombination med medfödd missbildning eller yttre avvikelser. Åtta av barnen hade en 
s.k. de novo CNV och sexton barn hade en nedärvd CNV från en förälder (i ett fall från 
båda). En möjlig men osäker association påvisades där en högre andel mödrar med 
egen CNV hade depression eller annan psykiatrisk diagnos före barnets födelse, jämfört 
med mödrar där ingen CNV identifierades. 
 
Sammanfattningsvis uppvisar barn med en tidig AST diagnos en stor variabilitet 
avseende hur svår deras autismproblematik är och avseende hur stor andel som har en 
samtidig lindrig till svår utvecklingsstörning. Det fanns i vår studerade grupp barn som 
helt saknade talat språk till barn med nära normal språkfunktion. En stor andel barn 
hade betydande samtidig hyperaktivitet. Epilepsi förekom hos nästan var tionde barn 
vid ålder 4.5 - 6.5 år.  
Inom gruppen barn som fått diagnos AST tidigt återfanns flera barn med neurologiska 
sjukdomar som tuberös skleros. Några hade andra väldefinierade syndrom som Fragile 
X och två flickor visade sig ha Rett syndrom. Extrem underburenhet och prenatal 
exponering för alkohol och epilepsiläkemedel bedömdes vara bidragande prenatala 
riskfaktorer hos några barn.  
 
Hög ålder hos fadern, utomeuropeisk förälder och om modern medicinerat med 
antidepressiv medicinering och/eller annan psykofarmaka ökade risken för AST hos 
barnet. Vi påvisade en markant skillnad där fäder och bröder till barn med AST hade 
högre förekomst av AST/broader phenotype medan särskilt mödrarna hade depression 
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och andra psykiska tillstånd. Underliggande förklaring kan vara att genetisk sårbarhet 
visar sig olika hos män och kvinnor samt att kvinnor oftare diagnosticeras med 
psykiatriska tillstånd utan att en AST problematik uppmärksammas. 
 
I uppföljningsstudien fann vi att de barn som diagnosticerats i låg ålder oftare hade ett 
samtidigt medicinskt eller genetisk tillstånd. Dessa barn hade en sämre adaptiv 
utveckling.  
 
I den avslutande genetiska studien med array-CGH identifierades avvikelser hos 8.6%, 
hälften nedärvda och hälften s.k. de novo.  
 
Avhandlingen belyser att barn med AST har mycket heterogena utvecklingsprofiler och 
en hög förekomst av utvecklingsneurologiska/neuropsykiatriska och medicinska 
tillstånd, inklusive epilepsi. Det går idag att identifiera genetiska orsaker till AST hos 
10-15% med hjälp av array-CGH, analys av Fragile X och andra mer riktade genetiska 
analyser. Vår rekommendation är att array-CGH bör ingå i utredning av barn med AST, 
särskilt vid samtidig utvecklingsstörning. Barn med AST bör ha tillgång till tidig 
intervention men även till medicinsk och genetisk utredning. Om diagnosen satts vid 
låg ålder behövs ofta en förnyad utredning efter ett par år, särskilt för att göra en 
noggrannare bedömning av den generella kognitiva förmågan.  
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